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 General introduction  11 
Epidemiology of lung cancer and risk factors 
At the beginning of the 20th century the diagnosis lung cancer was rarely made. 
Now it is worldwide the leading malignancy both in incidence and mortality. 
Every year, 1.2 million new cases of lung cancer are diagnosed (12.3% of all 
cancers worldwide) and 1.1 million patients die due to lung cancer (17.8% of all 
cancer deaths worldwide). The highest incidence rates are observed in North 
America and Europe.1 In Europe, there are nearly 400.000 new cases each 
year.2 Women account for 40 percent of all lung cancer cases and their rate is 
increasing, while the rate in males is beginning to decline. In the Netherlands, 
same opposite trends in incidence and mortality for lung cancer are described. 
During the period 1989-2000, the number of newly diagnosed lung cancers in 
males decreased from 7252 to 6391, whereas in females an increase from 
1299 to 2428 was reported.3 
The most important explanation for this difference is the change in smoking 
behaviour.4 Approximately, 85% to 90% of all patients with lung cancer have a 
history of direct exposure to tobacco. Several studies demonstrated a clear dose-
response relation between the development of lung cancer and the degree of 
exposure to cigarette smoke.5,6 Other risk factors of lung cancer include 
exposure to environmental tobacco smoke, asbestos and other occupational and 
environmental agents like radon, some metals (e.g., nickel, arsenic, cadmium), 
and ionising radiation.7,8 Also genetic factors and gender play a role in 
analysing risk factors. The risk of developing lung cancer increases in first 
degree relatives of lung cancer patients, independent to tobacco exposure, and 
in women.9 Potential biologic explanations include gender differences in nicotine 
metabolism, male-female variations in cytochrome P-450 enzymes, and the 
effect of hormones on the development of lung cancer.10 Some disease entities 
are associated with an increased risk of lung cancer. Patients with previously 
treated lung cancer or head and neck cancer have a higher risk of developing 
lung cancer.11,12 Also a number of benign lung diseases, like chronic obstructive 
pulmonary disease, tuberculosis, human immunodeficiency virus (HIV) infection 
or interstitial pulmonary fibrosis, confer a greater risk.13-15 
Biomarkers of carcinogenesis 
In recent years, progress in understanding the molecular events that occur 
during carcinogenesis has given more insight into the biology of lung cancer 
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and potentially significant determinants of prognosis.16,17 The development of 
lung cancer is a multistep process that results from a combination of carcinogen 
exposure and genetic and epigenetic alterations followed by clonal expansion. 
Chromosomal abnormalities identified in lung cancer include chromosomal 
aberrations and deletions. Typical features of the carcinogenic process are 
increased activity of growth stimulating genes, oncogenes, and insensitivity to 
anti-growth signals, produced by tumour suppressor genes. Oncogenes are 
dominant genes, whereas tumour suppressor genes are recessive genes. The 
latter genes are rendered inactive by chromosomal loss of one allele (loss of 
heterozygosity (LOH)) and damage to the other by genetic mutation or 
epigenetic hypermethylation. 
Important oncogenes are Ras genes, the epidermal growth factor receptor 
(EGFR), and HER-2/neu. Ras genes regulate signal transduction pathways that 
control cell growth. In NSCLC, especially adenocarcinoma, almost all mutations 
affect the K-ras gene. Tumours with K-ras mutations tend to have a worse 
prognosis.18 
Epidermal growth factor receptor (EGFR) is a member of the ERBB gene family, 
which is a group of transmembrane receptor tyrosine kinases. Activation plays 
an important role in cell division and differentiation. In some studies, expression 
of EGFR in NSCLC has been correlated with advanced disease stage and poor 
prognosis.19,20 Furthermore, expression of EGFR appears to upregulate a matrix 
metalloproteinase, which regulates tumour invasiveness. ZD 1839 is a specific 
inhibitor of the EGF activated tyrosine kinase, which is under investigation in 
several trials.21 
Another ERBB family member, HER2/neu is expressed in about 30% of NSCLC, 
especially adenocarcinoma. High levels are associated with the multiple drug 
resistance phenotype and increased metastatic potential.22 
An important tumour suppressor gene in lung cancer is the p53 gene. Deletions 
and point mutations in this gene are commonly acquired genetic lesions. The 
p53 gene plays a role in the regulation of transcription processes in the cell 
nucleus. Mutations affect both small cell lung cancers and non-small cell lung 
cancers. p53 expression is more frequently seen in squamous cell carcinomas 
and worsens the prognosis.23,24 
Angiogenesis is an important mechanism in tumour cell proliferation and 
metastatic capacity. Neovascularisation is stimulated by the production of 
vascular endothelial growth factor (VEGF). In NSCLC, increased levels of VEGF 
are generally associated with poor prognosis.25 Molecules targeting vascular 
endothelial growth factor (VEGF) or its receptor (VEGFR) seem to control tumour 
progression and may prolong survival. Several other biomarkers interfere with 
the process of angiogenesis and various angiogenesis inhibitors, like COX-2 
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inhibitors and matrix metalloproteinase inhibitors, are under evaluation in 
clinical trials.26,27 
Histology 
The currently used histological classification for lung cancer was developed by 
the World Health Organization (WHO) and is revised in 1999 (Table 1.1).28 The 
five main tumour categories include squamous cell carcinoma, adeno-
carcinoma, large cell carcinoma, adeno-squamous cell carcinoma and small 
cell carcinoma. Small cell lung cancer (SCLC), which counts for approximately 
20 percent of all lung cancers, arises from neuroendocrine cells.29 It is 
distinguished from non-small cell lung cancer (NSCLC) by its rapid doubling 
time, high growth fraction, and the early development of widespread 
metastases. Squamous cell carcinoma used to be the most common histological 
type, but recently a shift has been noted and now adenocarcinoma is the most 
frequent type, particularly in women and non-smokers.30,31 Histological 
characteristics of squamous cell carcinoma are intercellular bridging, squamous 
pearl formation, and keratin formation. Adenocarcinomas are a glandular 
epithelial malignancy with several histological subtypes, including acinar, 
papillary, bronchioloalveolar, and solid with mucus formation. Adenosquamous 
carcinomas have a mix of adeno- and squamous differentiation. Large cell 
carcinoma is a poorly differentiated NSCLC. 
Clinical features 
Early detection of lung cancer is difficult because it does not frequently produce 
symptoms in the beginning of the disease process. Approximately 2 to 15 
percent of the patients present without any symptoms.32 The vast majority of 
patients is symptomatic at the time of clinical presentation and presents with 
stage III or IV disease. Symptoms can be related to the primary lung tumour or 
to intrathoracic spread, distant metastasis, or paraneoplastic syndromes.33 
The most common symptoms related to the primary tumour or intrathoracic 
spread are cough, dyspnoea, haemoptysis, chest pain and hoarseness. About 
one third of patients present with symptoms as a result of distant metastases. 
Lung tumours frequently metastasize to the liver, bones, brains and adrenal 
glands. Paraneoplastic syndromes occur in about 10 to 20 percent of patients 
with a lung tumour and can cause endocrine/metabolic abnormalities, several 
neuromuscular and dermatologic syndromes, haematological abnormalities and 
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systemic symptoms, like clubbing, hypertrophic osteoarthropathy, fatigue and 
cachexia. Severe weight loss and poor performance status have a poor influence 
on survival.34 
 
Table 1.1.  1999 WHO classification of invasive malignant epithelial lung tumours 
Histological classification 
1   Squamous cell carcinoma 
 Variants: papillary, clear cell, small cell, basaloid 
2   Small cell carcinoma 
 Variant: combined small cell 
3   Adenocarcinoma 
 Acinar 
 Papillary 
 Bronchioloalveolar carcinoma 
  Non-mucinous 
  Mucinous 
  Mixed mucinous and non-mucinous or indeterminate 
 Solid adenocarcinoma with mucin formation 
 Adenocarcinoma with mixed subtypes 
 Variants: well-differentiated foetal adenocarcinoma, mucinous (colloid), 
 mucinous cystadenocarcinoma, signet ring, clear cell 
4   Large cell carcinoma 
 Variants: large cell neuroendocrine carcinoma, combined large cell neuroendocrine 
carcinoma, basaloid carcinoma, lymphoepithelioma-like carcinoma, clear cell 
carcinoma, large cell carcinoma with rhabdoid phenotype 
5   Adenosquamous carcinoma 
6   Carcinomas with pleomorphic, sarcomatoid or sarcomatous elements 
 Carcinomas with spindle and/or giant cells 
  Pleomorphic carcinoma 
  Spindle cell carcinoma 
  Giant cell carcinoma 
 Carcinosarcoma 
 Pulmonary blastoma 
 Others 
7   Carcinoid tumours 
 Typical carcinoid 
 Atypical carcinoid 
8   Carcinomas of salivary gland type 
 Mucoepidermoid carcinoma 
 Adenoid cystic carcinoma 
 Others 
9   Unclassified carcinoma 
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Diagnosis 
Once history, physical examination, or radiological findings suggest the 
presence of a malignant pulmonary lesion, further diagnostic evaluation is 
necessary to establish the diagnosis of lung cancer by tissue morphology (i.e. 
standard histology), to accurately stage the tumour, and to evaluate 
cardiopulmonary function if surgical treatment is considered. 
The American Thoracic Society (ATS) and the European Respiratory Society (ERS) 
recommend computed tomography (CT) scans of the thorax and upper 
abdomen to be obtained in all patients with NSCLC to adequately stage the 
patient by demonstrating invasion of the tumour in surrounding structures, 
enlarged mediastinal lymph nodes or metastases.35 However, CT evaluation of 
mediastinal lymph node metastases has its limitations. A meta-analysis 
examining the accuracy of CT in detecting positive mediastinal lymph nodes 
reported a sensitivity of 79 percent and a specificity of 78%, respectively.36 
Radiographic studies of the brain and bones should only be performed when 
symptoms are present suggesting metastatic disease.35,37 CT scanning can be 
useful in detecting cerebral metastases. Magnetic resonance imaging (MRI) is, 
however, taking over as the investigation of choice in this situation.38 MRI is also 
more accurate to prove invasion of the tumour into the mediastinum, great 
vessels, spine, and chest wall. It is particularly useful in evaluating tumours of 
the superior sulcus.39,40 Positron emission tomography (PET) scanning with 
fluoro-2-deoxyglucose (FDG) is a non-invasive, diagnostic imaging technique for 
measuring the metabolic activity of cells of the body. The use of PET scanning is 
based on the fact that most lung tumours have an increased rate of metabolism 
of glucose when compared to normal tissues. A high sensitivity of approximately 
97% and a high specificity of approximately 78% make it a useful diagnostic tool 
in evaluation of the primary tumour, mediastinum and distant metastases.41-43 
However, a PET scan can be false-positive in granulomas or other types of 
infection.44,45 False negative results are less frequent, and generally occur in 
carcinoid tumours, bronchioloalveolar carcinomas, or small tumours (<1 cm in 
diameter).46 PET scanning improves the detection rate of both local and distant 
metastases and may also avoid unnecessary surgery in patients who appear to 
have potentially resectable disease by conventional staging methods.47 The use 
of recently developed dual-modality PET/CT significantly increases the number 
of patients with correctly staged NSCLC and thus has a positive effect on 
treatment.48 
Sometimes the diagnosis of lung cancer can be established by sputum cytology, 
but in most patients invasive diagnostic procedures are necessary to achieve a 
histological or cytological diagnosis of the suspect lesion. Flexible, fiberoptic 
bronchoscopy is the most important diagnostic tool to obtain a tissue diagnosis. 
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It also gives information about operability by determining the endobronchial 
extent of the tumour or by detecting additional endobronchial lesions. Other 
invasive procedures to prove malignancy include thoracocentesis, thoracoscopy 
and transthoracic needle aspiration.  
Staging 
The purpose of a staging system is to define groups of patients based on 
pathology, with respect to treatment modalities and prognosis. Accurate staging 
is essential because the stage of the disease at the time of diagnosis represents 
one of the most important determinants of outcome in NSCLC, with earlier 
stages having a better chance of long-term survival. The international staging 
system for non-small cell lung cancer was conceptualised in the late 1940s.49 In 
1974, the American Joint Commission for Cancer (AJCC) introduced a more 
detailed staging system, which was revised in 1986 and 1997.50-52 
The staging system for lung cancer is based on the TNM classification. The T-
factor is used to describe the extent of the primary tumour, the N factor to 
describe the extent of regional lymph node involvement, and the M factor to 
describe the presence of distant metastases. Table 1.2 includes the TNM 
classification of the international staging system that has been updated in 1997.  
Based on the results of a group of 5319 patients treated for non-small cell lung 
cancer, the TNM subsets have been grouped in stages in order to assess 
prognosis and treatment. Stages I through III are divided into A and B 
subcategories (Table 1.3).  
Patients are first staged based on clinical information obtained by physical 
examination, radiographic imaging, bronchoscopy, mediastinoscopy, and/or 
any other investigation undertaken prior to thoracotomy. This staging is called 
cTNM (clinical). A post-surgical treatment-pathologic stage (pTNM) is based on 
the prior studies as well as the pathological evaluation of the resected tumour 
and lymph nodes. This staging is more precise than the clinical staging.  
Because the therapy of NSCLC is influenced by the presence of mediastinal 
lymph node metastases, it is essential to stage the mediastinum carefully. 
Cervical mediastinoscopy is the most accurate method to investigate the superior 
mediastinal lymph nodes.53 Regional lymph nodes are divided into stations 
based upon an internationally accepted schema.54 Intrapulmonary and hilar 
lymph nodes (N1) are indicated by double digits (station 10-14) and mediastinal 
lymph nodes (N2/3) are indicated by single digits (station 1-9). The lymph nodes 
accessible to cervical mediastinoscopy are right and left upper paratracheal 
(stations 2L and 2R), pretracheal (station 3), right and left lower paratracheal 
(stations 4R and 4L) and anterior subcarinal nodes (station 7). Posterior 
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subcarinal lymph nodes (station 7) and lymph nodes located in the 
aortopulmonary window (station 5) or para-aortic (station 6) can be reached by 
thoracoscopy, anterior mediastinotomy, or by endoscopic ultrasound 
echography (EUS). EUS can also establish a cytological diagnosis in para-
oesophageal lymph nodes (station 8) and pulmonary ligament lymph nodes 
(station 9).55 
 
Table 1.2.  TNM definitions# 
TNM definitions  
Tumour stage (T)  
TX Primary tumour cannot be assessed: presence of malignant cells without 
visible tumour 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour ≤3 cm in size, no invasion more proximal than the lobar 
bronchus 
T2 Tumour >3 cm in size; involvement of main bronchus≥2 cm distal to 
the carina; invasion of the visceral pleura; partial atelectasis 
T3 Tumour of any size invading the chest wall (including superior sulcus 
tumours), diaphragm, mediastinal pleura, pericardium; or tumour in 
main bronchus <2 cm distal to the main carina; or tumour associated 
with atelectasis / obstructive pneumonitis of the entire lung 
T4 Tumour of any size invading the mediastinum, heart, great vessels, 
oesophagus, trachea, vertebral body, or main carina; presence of 
malignant pleural or pericardial effusion; satellite tumour nodulus in the 
same lobe 
Nodal stage (N)  
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 Metastases of ipsilateral hilar and/or ipsilateral peribronchial lymph 
nodes, and intrapulmonary nodes involved by direct extension of 
primary tumour 
N2 Metastases of ipsilateral mediastinal and/ or subcarinal lymph nodes 
N3 Metastases of contralateral mediastinal or hilar lymph nodes or 
ipsilateral or contralateral scalene or supraclavicular lymph nodes 
 
 
 
Metastatic stage (M)  
Mx Distant metastases cannot be assessed 
M0 No evidence of distant metastases 
M1 Distant metastases present, including metastatic tumour nodule(s) in the 
non-primary tumour lobe 
# adapted from Mountain52 
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Table 1.3.  Stage grouping# 
Stage TNM subset 
0 Carcinoma in situ 
IA T1N0M0 
IB T2N0M0 
IIA T1N1M0 
IIB T2N1M0 
 T3N0M0 
IIIA T3N1M0 
 T1-3N2M0 
IIIB Any T N3M0 
 T4 any N M0 
IV any T, any N, M1 
# adapted from Mountain52 
Treatment 
The primary goal of lung cancer therapy is complete eradication of the disease. 
The therapeutic approach is based upon the histopathological type of tumour, 
the stage of the tumour, performance status and comorbidity. Treatment of lung 
cancer is multidisciplinary and needs close cooperation between the 
pulmonologist, surgeon and radiation therapist. After the initial therapy careful 
follow-up is essential for early detection and treatment of recurrent disease. 
Small cell carcinoma of the lung is managed primarily with systemic 
chemotherapy, due to its early development of distant metastases. Surgery 
remains the most curative modality for NSCLC. The goal of surgical treatment is 
to perform a complete resection. Resectability is closely related to the stage of 
the disease.  
Stage I and II 
The essential similarity between stage I and stage II is the absence of 
extrapulmonary lymph node involvement. Both stages are usually treated with 
surgery, assuming the patient has sufficient respiratory reserve. Adequate 
surgery usually consists of a lobectomy, bilobectomy, sleeve lobectomy, or a 
pneumonectomy with mediastinal node sampling for staging purposes. Lesser 
procedures are associated with higher rates of local recurrence and a trend 
toward decreased survival.56 Thoracoscopy or thoracotomy with limited resection 
is done by some in patients who cannot tolerate a lobectomy due to poor 
pulmonary function, and in elderly or high-risk patients.57 
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Patients who are inoperable for medical reasons are often referred for radiation 
therapy alone. However, the outcomes following radiation therapy alone for 
NSCLC are inferior to those achieved with surgical resection.58 In patients with 
incomplete resections, postoperative radiotherapy reduces local recurrence 
rates, but does not favourably affect survival.59,60 The addition of radiotherapy 
does also not improve survival in patients with a complete resection. 
Administration of postoperative chemotherapy or combined chemo-radiotherapy 
is currently not considered to be a standard therapy. At this moment, also the 
role of neo-adjuvant chemotherapy in resectable stage I and II NSCLC remains 
uncertain, as results of several studies are conflicting. Its use should be limited to 
patients enrolled in trials.61,62 
Stage III 
The treatment of patients with stage III disease is controversial. Stage IIIA was 
originally intended to imply regionally advanced, yet potentially resectable 
disease, while stage IIIB represented regionally advanced unresectable disease. 
However, the introduction of combined modality treatment has allowed patients 
with good performance status presenting with T4 (IIIB) tumours to undergo 
induction therapy, followed by reassessment of resectability. 
The aims of induction or neoadjuvant chemotherapy prior to resection or 
radiotherapy are to improve local control by downstaging the primary tumour 
and nodal metastases and to eradicate systemic micrometastases. Over the past 
years, many trials in regionally advanced NSCLC have been conducted to 
search the optimal combination of chemotherapy and to evaluate the role of 
multimodality therapy, consisting of combinations of chemotherapy and 
locoregional therapy (radiotherapy and/or surgery).63 A number of new agents 
were found to be effective against lung cancer, like docetaxel, gemcitabine, 
irinotecan, paclitaxel or vinorelbine. They have all been incorporated in a 
number of combination chemotherapeutic regimens, many of which included 
platinum based chemotherapy.  Until now, no regimen appears superior to 
another.64 Most trials also report that combined modality treatment is associated 
with better local control and survival than locoregional therapy alone.61,65,66 
Results of current programs are such that for patients with stage IIIA disease no 
specific regimen can be regarded as standard therapy. Trials examining the 
effect of surgery or radiotherapy after induction chemotherapy in stage IIIA are 
conducted and will help to define the optimal therapy for this group of patients. 
Patients with stage IIIB disease are suitable for combined modality treatment with 
chemotherapy and radiotherapy. Some selected patients with a T4 tumour, may 
be candidates for surgery after induction chemotherapy. 
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Stage IV 
Options for patients found to have stage IV disease are palliative chemotherapy 
or radiation therapy for the treatment of bronchial obstruction, painful bone 
metastases, or central nervous system metastases.67,68 Patients with good 
performance status and little weight loss are those most likely to respond to 
chemotherapy. Stage IV patients with significant comorbid illnesses may be 
candidates for best supportive care only. 
Regardless of histology or stage, unresectable tumours, which compromise the 
trachea or large airways, may be palliated by local techniques like 
brachytherapy, laser therapy, airway stents, and/or photodynamic therapy. 
Survival and prognosis 
Despite improvement in understanding the aetiology and treatment of lung 
cancer, survival has not clearly improved during the past decades. The expected 
5-year survival rate for all patients in whom lung cancer is diagnosed is 15%.69 
This poor prognosis is largely due to the advanced stage of the tumour at 
presentation, in which treatment rarely will result in cure. Five–year survival for 
these patients is less than 5%. Early stages of the disease offer the best 
prognosis, with a 5-year survival of 40-70%.52 The main prognostic factors for 
patients with lung cancer are tumour stage and performance status. Other 
factors include severe weight loss and presence of comorbidity precluding 
radical therapy. Although a 15% 5-year survival rate is meagre, a number of 
promising new diagnostic modalities and drugs are developed and have been 
incorporated into clinical trials. 
T3 and T4 non-small cell lung cancer 
Patients with advanced locoregional disease constitute a heterogeneous group. 
At present, they are divided into stage IIB (T3N0M0 tumours) and stage III (T3-
4N1-3M0). Prior to 1997, T3N0M0 tumours were also included in the stage III 
grouping, but because of their favourable outcome with resection they are now 
classified as stage IIB.52 The historical difference between T3 and T4 tumours is 
resectability. T3 tumours are generally resectable without requiring major 
surgery, whereasT4 tumours invade more vital structures, which complicates 
surgery. 
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T3 tumours 
T3 tumours comprise a heterogeneous group, including tumours with invasion of 
the chest wall, mediastinal structures, or diaphragm, Pancoast tumours, tumours 
with involvement of a main bronchus within 2 cm of the carina, and tumours 
associated with atelectasis or obstructive pneumonitis of the entire lung. Of 
patients who undergo thoracotomy for lung cancer, approximately 10% have a 
T3 tumour. These tumours have varying prognoses depending upon the 
completeness of resection and the patient’s lymph node status.70,71 Five-year 
survival rates are 38% and 25%, respectively for pT3N0 and pT3N1 tumours.52 
Some studies reported no significant difference in survival between the several 
subgroups.70,72 Other studies, however, demonstrated a survival benefit for 
tumours with chest wall invasion.73,74 The two largest groups of T3 tumours 
include tumours with chest wall invasion and tumours invading mediastinal 
structures. In approximately 80% of these patients a complete resection is 
achieved. Most studies about surgical resection of T3 tumours only include 
tumours with chest wall invasion. N0 disease is a common feature in this 
subgroup and has the best outcome with 5–year survival up to 49%.75 Surgery 
consists of either an extrapleural dissection or an en bloc resection. 
Controversial results have been reported for depth of invasion of the chest wall 
as being a prognostic factor.70,76,77 Completeness of resection is the most 
important prognostic factor. Postoperative radiotherapy does not improve 
survival.75-77 
Pancoast tumours can be staged as T3 or T4. Due to the localisation in the apex 
of the lung with invasion of adjacent structures, they cause characteristic 
symptoms, like arm or shoulder pain or Horner’s syndrome. The tumour can be 
resected by the classic posterior Shaw-Paulson approach or the newer anterior 
transcervical approach, introduced by Dartevelle. Regarding the extent of 
pulmonary resection, en bloc resection of the involved ribs with a lobectomy is 
recommended. The 5-year survival of pre-operative radiotherapy and resection 
is about 27%.78 Recent multimodality studies, involving chemoradiotherapy and 
surgical resection, show promising results regarding completeness of resection, 
local recurrence and survival.79 
Few studies are published about patients with lung tumours invading the 
diaphragm, because these tumours are very rare.80,81 In most cases, 
diaphragmatic involvement is diffuse or very deep, which makes complete 
resection impossible. In selected patients combined resection of the lung and 
diaphragm is possible with reasonable survival results. 
Central T3 tumours include tumours with invasion of mediastinal structures and 
tumours located in the main bronchus within 2 cm of the carina. In this 
subgroup, squamous cell carcinomas form a frequent histological subtype.70 
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Surgery mostly consists of a pneumonectomy or sleeve lobectomy and results are 
best for patients with T3N0 tumours due to proximity to the carina. Five-year 
survival for all patients is 25%.71 Tumours with extension into mediastinal 
structures have invasion of the mediastinal pleura, pericardium, or phrenic 
nerve. Regarding the invasion of these structures, there is no significant 
difference in survival. For patients with minimal invasion of the mediastinal 
pleura surgery is the treatment of choice. Most of these patients are 
peroperatively staged as T3. In patients presenting with invasion of the 
mediastinum on CT scanning or MRI, it may be difficult to distinguish T3 from T4 
tumours. 
T4 tumours 
Characterisation of the primary tumour as T4 involves the presence of any of the 
following: invasion of the mediastinum, heart or great vessels, trachea, 
oesophagus, vertebral body, or the carina, the presence of a malignant pleural 
or pericardial effusion or satellite tumour nodule(s) within the same lobe as the 
primary tumour. Thus T4 tumours also encompass heterogeneous subgroups. As 
surgery is not accessible for patients with a T4 tumour due to presence of 
malignant pleural or pericardial effusion, its role for T4 tumours invading 
adjacent structures remains doubtful. Some studies about extended resection of T4 
tumours have been published and surgery appears to be beneficial and radical 
resection of the tumour has a potential for cure in the absence of mediastinal 
lymph node metastases.82 However, hospital morbidity and mortality are high. Best 
results have been reported in selected patients with carinal or tracheal 
invasion.82,83 The outcome in patients with invasion of the oesophagus or 
vertebrae is poor and these tumours mostly are considered unresectable.84,85 
Under the new staging system T4 tumours also include carcinomas with a 
satellite tumour in the same lobe. It is sometimes difficult to examine if these 
lesions are metastases of the primary tumour or a second primary. The outcome 
of this subgroup is significantly better than of patients with invasion of vital 
structures.85,86 
Recently, preoperative chemotherapy or chemoradiotherapy in patients with T4 
tumours has been reported in several trials with encouraging results.87,88 
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Outline of the thesis 
Surgical resection is the treatment of choice in patients with non-small cell lung 
cancer in the absence of distant metastases. Resectability is closely related to the 
stage of the disease. Whereas stage I and stage II tumours are considered to be 
resectable, the role of surgery for stage III tumours remains unclear. The studies 
in this thesis were performed to clarify the role of surgical treatment of T3 and 
T4 tumours by analysing the characteristics and prognosis of several subgroups. 
 
The best operative procedure for lung cancer with chest wall invasion (T3) is still 
controversial. In chapter 2 results of 125 patients who underwent either en bloc 
resection or extrapleural dissection for non-small cell lung cancer invading the 
chest wall are analysed in order to evaluate these operative procedures and to 
determine survival characteristics. 
 
Chapter 3 describes the results of surgery of 2 other subgroups of patients with 
a T3 tumour. Results of resection of T3 tumours invading mediastinal structures 
(mediastinal pleura, pericardium, or phrenic nerve) and of T3 tumours located 
in the main bronchus less than 2 cm distal to the main carina are studied to 
investigate survival characteristics. 
 
In chapter 4 recent literature on Pancoast tumours is reviewed. These tumours 
can be staged as either T3 or T4. Clinical characteristics, diagnosis, and tumour 
staging are studied. Also several treatment possibilities, survival, as well as 
recurrence and prognostic factors are discussed. 
 
Because of localisation and invasion of surrounding structures, the role of 
surgical treatment for T4 tumours is doubtful. Extended resections carry a high 
mortality and should be restricted for selected patients. Chapter 5 gives the 
results of surgical resection of T4 non-small cell lung cancer in 89 patients and 
clarifies the selection-process. 
 
Recently, multimodality treatment has become the standard therapy for patients 
with locally advanced tumours. In chapter 6 the role of surgery after 
neoadjuvant chemotherapy in patients with stage IIIB non-small cell lung cancer 
was evaluated. The diagnostic value of repeat mediastinoscopy after 
neoadjuvant chemotherapy for mediastinal staging was also analysed. 
 
Chapter 7 presents the summary and conclusion of the thesis. 
 24  Chapter 1 
References 
1 Parkin D. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43. 
2 Tyczynski J, Bray F, Parkin D. Lung cancer in Europe in 2000: epidemiology, prevention, and 
early detection. Lancet Oncol 2003;4:45-55. 
3 Visser O, Siesling S, Van Dijck JA. Incidence of cancer in the Netherlands 1999/2000. 2003, 
Utrecht, Vereniging van Intergrale kankercentra.  
4 Ruano-Ravina A, Figueiras A, Barros-Dios J. Lung cancer and related risk factors: an update of 
the literature. Public Health 2003;117:149-56. 
5 Alberg A, Samet J. Epidemiology of lung cancer. Chest 2003;123:21S-49S. 
6 Lee P. Lung cancer and type of cigarette smoked. Inhal Toxicol 2001;11:951-76. 
7 Zhong L, Goldberg M, Parent M, Hanley J. Exposure to environmental tobacco smoke and the 
risk of lung cancer: a meta-analysis. Lung Cancer 2000;27:3-18. 
8 Steenland K, Loomis D, Shy C, Simonsen N. Review of occupational lung carcinogens. Am J 
Ind Med 1996;29:474-90. 
9 Brownson R, Alavanja M, Caporaso N, Berger E, Chang J. Family history of cancer and risk of 
lung cancer in lifetime non-smokers and long-term ex-smokers. Int J Epidemiol 1997;26: 
256-63. 
10 Zang E, Wyder E. Differences in lung cancer risk between men and women: examination of the 
evidence. J Natl Cancer Inst 1996;88:183-92. 
11 Leong P, Rezai B, Koch W, Reed A, Eisele D, Lee D, Sidransky D, Jen J, Westra W. 
Distinguishing second primary tumours from lung metastases in patients with head and neck 
squamous cell carcinoma. J Natl Cancer Inst 1998;90:972-7. 
12 Thomas P, Rubinstein L, and the Lung Cancer Study Group. Cancer recurrence after resection: 
T1N0 non-small cell lung cancer. Ann Thorac Surg 1990;49:242-7. 
13 Kuller L, Ockne J, Meilahn E, Svendsen K. Relation of forced expiratory volume in one second 
(FEV1) to lung cancer mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Am J 
Epidemiol 1990;132:265-74. 
14 Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A 
population-based cohort study. Am J Respir Crit Care Med 2000;161:5-8. 
15 Parker M, Leveno D, Campbell T, Worrell J, Carozza S. AIDS-related bronchogenic carcinoma: 
fact or fiction? Chest 1998;113:154-61. 
16 Shields P. Molecular epidemiology of lung cancer. Ann Oncol 1999;10:S7-11. 
17 Rom W, Hay J, Lee T, Jiang Y, Tchou-Wong K. Molecular and genetic aspects of lung cancer. 
Am J Respir Crit care Med 2000;161:1355-67. 
18 Graziano S, Gamble G, Newman N, Abbott L, Rooney M, Mookherjee S, Lamb M, Kohman L, 
Poiesz B. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I 
and II non-small cell lung cancer. J Clin Oncol 1999;17:668-75.  
19 Selvaggi G, Novell S, Torri V, Leonardo E, De Guili P, Borasio P, Mossetti C, Ardissone F, Lausi 
P, Scagliotti G. Epidermal growth factor receptor overexpression correlates a poor prognosis in 
completely resected  non-small cell lung cancer. Ann Oncol 2004;15:28-32. 
20 Brabender J, Danenberg K, Metzger R, Schneider P, Park J, Salonga D, Holscher A, Danenberg 
P. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung 
cancer is correlated with survival. Clin Cancer Res 2001;7:1850–5. 
21 Johnson D. Gefitinib (Iressa) trials in non-small cell lung cancer. Lung Cancer 2003;41:S23-8. 
22 Rachwal W, Bongiorno P, Orringer M. Expression and activation of erbB-2 and epidermal 
growth factor receptor in lung adenocarcinomas. Br J Cancer 1995;72:56-64. 
23 Minna J. The molecular biology of lung cancer pathogenesis. Chest 1993;103:449S–56S. 
24 Greenblatt M, Bennett W, Hollstein M, Harris C. Mutations in the p53 tumour suppressor gene: 
clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78. 
 General introduction  25 
25 Niklinska W, Burzykowski T, Chyczewski L, Niklinski J.  Expression of vascular endothelial 
growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene 
mutation and prognosis. Lung Cancer 2001;34:S59-64. 
26 Altorki N, Keresztes R, Port J, Libby D, Korst R, Flieder D, Ferrara C, Yankelevitz D, 
Subbaramaiah K, Pasmantier M, Dannenberg A. Celecoxib, a selective cyclo-oxygenase-2 
inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-
small-cell lung cancer. J Clin Oncol 2003;21:2645-50. 
27 Liu J, Tsao M, Pagura M, Shalinsky D, Khoka R, Fata J, Johnston M. Early combined treatment 
with carboplatin and the MMP inhibitor, prinostat, prolongs survival and reduces system 
metastasis in an aggressive orthotopic lung cancer model. Lung cancer 2003;42:335-44. 
28 Travis W, Colby T, Corrin B, Shimosato Y, Brambilla E. Histologic and graphical text slides for 
the histological typing of lung and pleural tumours. In: World Health Organization Pathology 
Panel: International Histological Classification of Tumours. Springer-Verlag Berlin, 1999 
29 Fry W, Menck H, Winchester D.The National Cancer Data Base report on lung cancer. Cancer 
1996;77:1947-55. 
30 Travis W, Lubin J, Ries L, Devesa S. United States lung carcinoma incidence trends: declining 
for most histologic types in males, increasing among females. Cancer 1996;77:2464-70. 
31 Janssen-Heijnen M, Nab H, van Reek J, van der Heijden L, Schipper R, Coebergh J. Striking 
changes in smoking behaviour and lung cancer incidence by histological type in South-east 
Netherlands, 1960-1991. Eur J Cancer 1995;31A:949-52. 
32 Chute C, Greenberg E, Baron J, Korson R, Baker J, Yates J. Presenting conditions of 1539 
population based lung cancer patients by cell type and stage in New Hampshire and Vermont. 
Cancer 1985;56:2107-11. 
33 Feruson M. Diagnosis and staging of non-small cell lung cancer. Hemat Oncol Clin North Am 
1990;4:1053-68. 
34 Pater J, Loeb M. Non-anatomic prognostic factors in carcinoma of the lung: a multivariate 
analysis. Cancer 1982;50:326-31. 
35 Pretreatment evaluation of non-small cell lung cancer. The American Thoracic Society and The 
European Respiratory Society. Am J Crit Care Med 1997;156:320-32. 
36 Dales R, Stark R, Raman S. Computed tomography to stage lung cancer. Approaching a 
controversy using meta-analysis. Am Rev Respir Dis 1990;141:1096-101. 
37 Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. 
Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin 
Oncol1997;15:2996-3018.  
38 Yokoi K, Kamiya N, Matsuguma H, Machida S, Hirose T, Mori K, Tominaga K. Detection of 
brain metastases in potentially operable non-small cell lung cancer. A comparison of CT and 
MRI. Chest 1999;115:714-9. 
39 Bittner RC, Felix R. Magnetic resonance (MR) imaging of the chest: state-of–the–art. Eur Resp J 
1998;11:1392-404. 
40 van Es HW. MRI of the brachial plexus. Eur Radiol 2001;11:325-36. 
41 Pieterman R, van Putten J, Meuzelaar J, Mooyaart E, Vaalburg W, Koeter G, Fidler V, Pruim J, 
Groen H. Pre-operative staging of non-small cell lung cancer with positron emission 
tomography. N Eng J Med 2000;343:254-61. 
42 Vansteenkiste J, Stroobants S. The role of positron emission tomography with 18F-fluoro-2-
deoxy-D-glucose in respiratory oncology. Eur Respir J 2001;17:802-20. 
43 Weder W, Schmid R, Bruchhaus H, Hillinger S, von Schulthess G, Steinert H. Detection of 
extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 
1998;66:886-92. 
44 Lowe V, Fletcher J, Gobar L, Lawson M, Kirchner P, Valk P, Karis J, Hubner K, Delbeke D, 
Heiberg E, Patz E, Coleman R. Prospective investigation of positron emission tomography in 
lung nodules. J Clin Oncol 1998;16:1075-84. 
 26  Chapter 1 
45 Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder L, Reske S. Lymph node staging in non-
small cell lung cancer: evaluation by [18F] FDG positron emission tomography (PET). Thorax 
1997;52:438-41.  
46 Lowe V, Naunheim K. Positron emission tomography in lung cancer. Ann Thorac Surg 
1998;65:1821-9. 
47 van Tinteren H, Hoekstra O, Smit E, van den Bergh J, Schreurs A, Stallaert R, van Velthoven P, 
Comans E, Diepenhorst F, Verboom P, van Mourik J, Postmus P, Boers M, Teule G. 
Effectiveness of positron emission tomography in the preoperative assessment of patients with 
suspected non-small cell lung cancer: the PLUS multicentre randomised trial. Lancet 
2002;359:1388-92. 
48 Antoch G, Stattaus J, Nemat A, Marnitz S, Beyer T, Kuehl H, Bockisch A, Debatin J, 
Freudenberg L. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. 
Radiology 2003;229:526-33. 
49 Denoix P. Enquete permanent dans les centres anticancereaux. Bull Inst Nat Hyg Paris 
1946;1:70-5. 
50 Mountain C, Carr D, Anderson W. A system for the clinical staging of lung cancer.  Am J 
Roentgenol Radium Ther Nucl Med 1974;120:130-8.  
51 Mountain C. A new international staging system for lung cancer. Chest1986;89(suppl): 
225s-33s. 
52 Mountain C. Revisions in the international system for staging lung cancer. Chest 
1997;111:1710-7. 
53 Hammoud Z, Anderson R, Meyers B, Guthrie T, Roper C, Cooper J, Patterson G. The current 
role of mediastinoscopy in the evaluation of thoracic disease. J Thorac Cardiovasc Surg 
1999;118:894-9.  
54 Mountain C, Dresler C. Regional lymph node classification for lung cancer staging. Chest 
1997;111:1718-23.  
55 Fritscher-Ravens A. Endoscopic ultrasound evaluation in the diagnosis and staging of lung 
cancer. Lung Cancer 2003;41:259-6. 
56 Ginsberg R, Rubinstein L. Randomized trial of lobectomy versus limited resection for T1 N0 
non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;60:615-22. 
57 British Thoracic Society, Society of Cardiothoracic Surgeons of Great Britain and Ireland 
Working Party. BTS guidelines: guidelines on the selection of patients with lung cancer for 
surgery. Thorax 2001;56:89-108. 
58 Sibley G. Radiotherapy for patients with medically inoperable Stage I non-small cell lung 
carcinoma: smaller volumes and higher doses-a review. Cancer 1998; 82:433-8. 
59 Stephens R, Girling D, Bleehen N, Moghissi K, Yosef H, Machin D. The role of post-operative 
radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with 
pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer 
Working Party. Br J Cancer 1996;74:632-9. 
60 Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis 
of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists 
Group. Lancet 1998; 352:257-67. 
61 Scott W, Howington J, Movsas B. Treatment of stage II non-small cell lung cancer. Chest 
2003;123:188S-201S. 
62 Cullen M. Lung cancer: chemotherapy for non-small cell lung cancer: the end of the 
beginning. Thorax 2003;58:352-6. 
63 Eberhardt W, Hepp R, Korfee S, Stamatis G. Current status of adjuvant and neo-adjuvant 
chemotherapy in resectable non-small cell lung cancer. Eur Respir Rev 2002;12:196-8. 
64 Ettinger DS. Is There a Preferred Combination Chemotherapy Regimen for Metastastic Non-
Small Cell Lung Cancer? The Oncologist 2002;7:226-33.  
65 Einhorn L. Neoadjuvant and adjuvant trials in non-small cell lung cancer. Ann Thorac Surg 
1998;65:208-11. 
 General introduction  27 
66 DeCamp M, Rice T, Adelstein D, Chidel M, Rybicki L, Murthy S, Blackstone E. Value of 
accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer. J Thorac 
Cardiovasc Surg 2003;126:17-27. 
67 Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan 
TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J. Gemcitabine plus 
best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial 
with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell 
Lung Cancer. Br J Cancer. 2000 ;83:447-53. 
68 Langendijk J, ten Velde G, Aaronson N, de Jong J, Muller M, Wouters E. Quality of life after 
palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat oncol 
Biol Phys. 2000;47:149-55.  
69 Gloeckler Ries L, Reichman M, Lewis D, Hankey B, Edwards B. Cancer Survival and Incidence 
from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 
2003;8:541-52. 
70 Riquet M, Lang L, Le Pimpec F, Dujon A, Souilamas R, Danel C, Manac’h D. Characteristics 
and prognosis of resected T3 non-small cell lung cancer. Ann Thorac Surg 2002;73:253-8. 
71 Scott W, Howington J, Movsas B. Treatment of stage II non-small cell lung cancer. Chest 
2003;123:188S-201S.  
72 Mountain C. Expanded possibilities for surgical treatment of lung cancer. Survival in stage IIIA 
disease. Chest 1990;97:1045-51. 
73 Detterbeck F, JSocinski M. IIB or not IIB: the current question in staging non-small cell lung 
cancer. Chest 1997;112:229-34. 
74 Inoue K, Sato M, Fujimura S. Prognostic assessment of 1310 patients with non-small cell lung 
cancer who underwent complete resection from 1980-1993. J Thorac Cardiovasc Surg 
1998;116:407-11. 
75 Downey R, Martini N, Rusch V, Bains M, Korst R, Ginsberg R. Extent of chest wall invasion and 
survival in patients with lung cancer. Ann Thorac Surg 1999;68:188-93. 
76 Chapelier A, Fadel E, Macchiarini P, Lenot B, Ladurie F, Cerrina J, Dartevelle P. Factors 
affecting long-term survival after en bloc resection of lung cancer invading the chest wall. Eur J 
Cardiothorac Surg 2000;18:513-8. 
77 Magdeleinat P, Alifano M, Benbrahem C, Spaggiari L, Porrello C, Puyo P, Levasseur P, 
Regnard J. Surgical treatment of lung cancer invading the chest wall: results and prognostic 
factors. Ann Thorac Surg 2001;71:1094-9. 
78 Detterbeck F. Pancoast (superior sulcus) tumours. Ann Thorac Surg 1997;63:1810-8. 
79 Rusch V, Giroux D, Kraut M, Crowley J, Hazuka M, Johnson D, Goldberg M, Detterbeck F, 
Shepherd F, Burkes R, Winton T, Deschamps C, Livingston R, Gandara D. Induction 
chemoradiation and surgical resection for non-small cell lung carcinomas of the superior 
sulcus: Initial results of the Southwest oncology group trial 9416 (intergroup trial 0160). J 
Thorac Cardiovasc Surg 2001;121:472-83.  
80 Rocco G, Rendina E, Meroni A, Venuta F, Della Pona C, De Giacomo T, Robustellini M, Rossi 
G, Massera F, Vertemati G, Rizzi A, Coloni G. Prognostic factors after surgical treatment of 
lung cancer invading the diaphragm. Ann Thorac Surg 1999;68:2065-8. 
81 Yokoi K, Tsuchiya R, Mori T, Nagai K, Furukawa T, Fujimura S, Nakagawa K, Ichinose Y. 
Results of surgical treatment of lung cancer involving the diaphragm. J Thorac Cardiovasc Surg 
2000;120:799-805. 
82 Detterbeck F, Jones D, Kernstine K, Naunheim K. Special treatment issues. Chest 
2003;123:244S-58S. 
83 Doddoli C, Rollet G, Thomas P, Ghez O, Seree Y, Giudicelli R, Fuentes P. Is lung cancer surgery 
justified in patients with direct mediastinal invasion? Eur J Cardiothorac Surg 2001;20:339-43. 
84 Grunenwald D. Surgery for advanced stage lung cancer. Semin Surg Oncol 2000;18:137-42. 
85 Osaki T, Sugio K, Hanagiri T, Takenoyama M, Yamashita T, Sugaya M, Yasuda M, Yasumoto K. 
Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. Ann Thorac 
Surg 2003;75:1745-51. 
 28  Chapter 1 
86 Yano M, Arai T, Inagaki K, Morita T, Nomura T, Ito H. Intrapulmonary satellite nodule of lung 
cancer as a T factor. Chest 1998;114:1305-8. 
87 Rendina E, Venuta F, De Giacomo T, Ciccone A, Ruvolo G, Coloni G, Ricci C. Induction 
chemotherapy for T4 centrally located non-small cell lung cancer. Thorac Cardiovasc Surg 
1999;117:225-33. 
88 Albain K, Crowley J, Turrisi  A, Gandara D, Farrar W, Clark J, Beasley K, Livingston R. 
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell 
lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 
2002;15:3454-60. 
 
  
 
CHAPTER 2 
Surgical treatment of 125 
patients with non-small cell  
lung cancer and chest wall 
involvement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCM Pitz, A Brutel de la Rivière, HRJ Elbers, 
CJJ Westermann, JMM van den Bosch 
 
Thorax 1996;51:846-50 
 30  Chapter 2 
Abstract 
Background 
The optimum operative procedure for lung cancer with chest 
wall invasion (T3) remains controversial. In this study, results of 
en bloc resection and extrapleural dissection are reviewed to 
determine survival characteristics. 
 
Methods 
Between 1977 and 1993, 125 patients underwent surgery for 
primary non-small cell lung cancer with chest wall invasion. 
Patients with superior sulcus tumours, metastatic carcinomas, 
synchronous tumours or recurrences were excluded. 
Extrapleural dissection was performed in 73 patients and en 
bloc resection (range 1 to 4 ribs) in 52. Resection was regarded 
as complete in 86 and incomplete in 39 patients. Actuarial 
survival time was estimated and risk factors for late death were 
identified.    
 
Results 
Hospital mortality was 3.2% (n=4). Estimated mean 5-year 
survival was 24% for all hospital survivors (n=121), 11% for 
patients with incomplete resection, and 29% for patients having a 
complete resection. In patients who underwent complete resection, 
mediastinal lymph node involvement and intrapleural tumour spill 
worsened the prognosis. Patients with adenocarcinoma had a 
better chance of long term survival. No relationship was found 
between survival and age, type of operative procedure, depth of 
chest wall invasion and postoperative radiotherapy. 
 
Conclusion 
Both operative procedures show reasonable survival results. 
Incomplete resection, mediastinal lymph node involvement, and 
intrapleural tumour spill adversely influence survival.  
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Introduction 
Surgical resection of non-small cell lung tumours and regional lymph nodes is 
the treatment of choice in the absence of distant metastases. 
Of patients who undergo thoracotomy for lung cancer, 5-8% have chest wall 
invasion.1-3 The prognostic implication of this finding has been disputed and, 
formerly, thoracic wall involvement was considered to be irresectable and 
unfavourable. Good survival rates after en bloc resection were first reported by 
Coleman in 19474 and Grillo et al. in 19661, and subsequent reports have 
supported the surgical treatment of these tumours.3,5-7 
In this retrospective study we have analysed our experience of 125 patients who 
underwent either en bloc resection or extrapleural dissection for non-small cell 
lung cancer involving the chest wall in order to evaluate these operative 
procedures and to determine survival characteristics. 
Patients and methods 
Two thousand and nine patients with lung cancer underwent resection at our 
hospital between January 1977 and December 1993, of whom 125 patients 
(6.2%) had a primary non-small cell lung cancer with chest wall invasion. 
Patients with distant metastases at presentation were excluded as were patients 
with superior sulcus tumours, synchronous tumours, metastatic carcinomas, and 
recurrent disease. All patients had tumour involvement of the parietal pleura or 
the skeletal muscles or ribs at pathological examination and were staged as T3 
according to the TNM classification.8 Resection was regarded as complete when 
the surgeon felt certain that all visible disease was removed, resection margins 
were free at pathological examination, and the highest mediastinal lymph node 
was negative at microscopy. In some patients, the tumour was opened by 
chance during surgery. This peroperative tumour spill was scored separately. 
The ages of the patients ranged from 34 to 80 years with a mean of 62.4 years. 
There were 111 men, and 114 patients were smokers. Presenting symptoms 
included chest pain in 72 patients (57.6%), cough in 58 patients (46.4%), 
dyspnoea in 44 patients (35.2%) and haemoptysis in 30 patients (24%). Twenty-
four patients (19.2%) were asymptomatic.  
A histological or cytological diagnosis was obtained preoperatively in 103 
patients (82.4%). Bronchoscopy was diagnostic in 60 (58.3%), percutaneous 
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needle aspiration biopsy in 33 (32.1%), cervical mediastinoscopy in 6 (5.8%), rib 
puncture in 2 (1.9%) and sputum cytology in 2 patients (1.9%). 
When invasion of the thoracic wall was proven pre-operatively by pathological 
examination, en bloc resection was performed. Otherwise, the decision as to 
which operative procedure should be performed was made peroperatively by 
the surgeon. Extrapleural dissection was performed when the parietal pleura 
was easily removed from the ribs, but en bloc resection was used when there 
was fixation of the tumour to the thoracic wall.  
Follow-up was completed in all patients in January 1995. Survival was estimated 
from the date of operation, using the Kaplan-Meier survival analysis method.9 
Hospital deaths were excluded. Differences in observed survival between groups 
were tested for statistical significance using the log-rank test.10 Incremental risk 
factors affecting survival were evaluated using Cox's proportional hazards 
model.11 
Results 
Cervical mediastinoscopy was negative in 112 patients (89.6%). Eight patients 
had positive lymph nodes at mediastinoscopy. The decision to proceed to 
surgery in these cases was based on their young age in four patients, a single 
positive lymph node at the ipsilateral tracheobronchial angle in three patients, 
and at the patient's own request in the remaining case. Cervical 
mediastinoscopy was not performed in 5 patients. Table 2.1 shows the extent of 
pulmonary resection. In 1 patient who had a bullectomy and pleurectomy 
because of persistent pneumothorax, the tumour was an incidental finding at 
pathological examination. One patient underwent a combined lobectomy and 
coronary artery revascularisation. 
 
Table 2.1. Extent of pulmonary resection in all patients (n=125) and those who underwent 
complete resection (n=86) 
Operative procedure All patients Patients with complete resection 
 Extrapleural 
(n=73) 
En bloc 
(n=52) 
Extrapleural 
(n=45) 
En bloc 
(n=41) 
Pneumonectomy  19  5  15  5 
Bilobectomy  1  1  1  1 
Lobectomy + segmental / wedge resection  2  9  1  8 
Lobectomy  44  31  23  22 
Segmental resection  5  5  5  5 
Wedge resection  1  1  0  0 
Bullectomy/pleurectomy  1  0  0  0 
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In 52 patients a combined en bloc resection of the carcinoma and chest wall 
was performed. The number of resected ribs ranged from 1 to 4: one in 10 
patients, two in 20 patients, three in 14 patients, four in 8 patients. 
Reconstruction of the chest wall by Marlex mesh was necessary in 11 of 52 
patients. No prosthetic materials were used in any other instance to fill the 
defect. There were no wound complications. Resection was judged to be 
complete in 41 patients. The remaining 73 patients underwent an extrapleural 
dissection which was complete in 45 patients. 
The tumour was opened by chance peroperatively in 8 of 125 patients. 
Table 2.2 shows tumour cell type and pTNM staging of all patients and those 
with complete resection. One patient who had a bullectomy and pleurectomy 
was staged as T3NxM0 because he had no cervical mediastinoscopy and no 
lymph nodes were sampled peroperatively. 
 
Table 2.2. Cell types and pTNM staging in all patients (n=125) and those who underwent complete 
resection (n=86) 
Variable All patients 
(n=125) 
Patients with complete resection 
(n=86) 
Cell type   
 Squamous cell carcinoma  69  48 
 Adenocarcinoma  42  30 
 Adenosquamous carcinoma  13  7 
 Large cell carcinoma  1  1 
pTNM staging    
 pT3N0M0  71  52 
 pT3N0M1  2  0 
 pT3N1M0  24  19 
 pT3N1M1  1  0 
 pT3N2M0  25  15 
 pT3N3M0  1  0 
 pT3NxM0  1  0 
 
The depth of chest wall invasion is shown in Table 2.3. In the group of 72 
patients with only parietal pleura involvement, a complete resection was 
obtained in 44 patients who underwent extrapleural dissection and in 9 patients 
who had en bloc resection. Extrapleural dissection was incomplete at the parietal 
pleura in 4 patients. The remaining 12 patients had an incomplete resection 
because of positive resection margins at the bronchus, tumour involvement of 
adjacent organs or of mediastinal lymph nodes, or distant metastases. In 
patients who underwent en bloc resection, 3 resections were judged to be 
incomplete because of positive mediastinal lymph nodes or a positive resection 
margin at the subclavian artery. 
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Table 2.3. Depth of chest wall invasion in all patients (n=125) and in those who underwent 
complete resection (n=86) 
Invasion of chest wall All patients Patients with complete resection 
 Extrapleural 
(n=73) 
En bloc 
(n=52) 
Extrapleural 
(n=45) 
En bloc 
(n=41) 
Parietal pleura  60  12  44  9 
Intercostal muscles/ribs   13  39  1  32 
Transverse processes  0  1  0  0 
 
Tumour involvement extended beyond the parietal pleura in 53 patients. An 
extrapleural dissection was performed in 13 patients, which was incomplete in 
12. In 2 patients postoperative biopsy specimens of the thoracic wall showed 
tumour involvement, although the surgeon was certain that all tumour had been 
removed.  Complete resection was achieved in 32 patients who underwent en 
bloc resection and 1 patient who underwent extrapleural dissection. In this 
patient, who had involvement of the intercostal muscles and the periosteum of 
the second rib, an extrapleural dissection with resection of the periosteum and 
part of the intercostal muscles was performed which was judged to be complete. 
Three patients received preoperative radiotherapy (30 Gy) to reduce the size of 
the tumour. 
Postoperative radiation therapy was given to 60 patients in doses of 27-66 Gy. 
Thirty-three patients who had complete resection received postoperative 
radiotherapy. Thirteen of these had mediastinal lymph node metastases and all 
were treated with postoperative radiotherapy at the mediastinum. The remaining 
27 patients were irradiated postoperatively at the mediastinum or the chest wall 
because of incomplete resection. 
Preoperative chemotherapy was given to 1 patient who had a positive ipsilateral 
paratracheal lymph node at cervical mediastinoscopy. Four patients received 
postoperative chemotherapy because of incomplete resection (n=3) and lung 
metastases (n=1). 
The overall hospital mortality was 3.2% (n=4). Two deaths were due to 
respiratory failure, 1 to sepsis and 1 to myocardial infarction. Three deaths 
followed extrapleural dissection and one followed en bloc resection. All these 
patients had a lobectomy. The estimated mean 5-year survival for all 125 
patients was 23%, and for hospital survivors (n=121) it was 24%.  
Complete resection was achieved in 83 hospital survivors (68.6%) and these 
patients had a mean 5-year survival of 29%. Thirty-eight patients who had an 
incomplete resection had a mean 5-year survival of only 11% (p<0.001) (Figure 
2.1). 
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Figure 2.1.  Estimated survival in patients with complete resection (——) and incomplete resection  
 (- - -). + = censored cases. 
 
 
Because of the significant difference in survival between hospital survivors who 
underwent complete and incomplete resection, it was decided to analyse only 
the results of those 83 who had complete resection with regard to other survival 
characteristics. In the univariate analysis survival was strongly related to 
mediastinal lymph node involvement. The mean 5-year survival for patients with 
N0 tumours was 36% compared with 23% and 14%, respectively, for those with 
N1 and N2 tumours. The difference between N0 and N2 tumours was 
statistically significant (p<0.05) (Figure 2.2).  
Similarly, survival was related to spill of tumour (Figure 2.3). The tumour was 
opened peroperatively in 7 of 121 hospital survivors, all of whom died within 16 
months because of distant metastases (n=4), respiratory failure (n=2), and local 
recurrence (n=1). Patients without intrapleural tumour spill had a mean 5-year 
survival of 32% (p<0.0001). 
Patients with adenocarcinoma had a better mean 5-year survival (40%) than 
those with squamous cell carcinoma (26%), although the difference was not 
statistically significant.  
Age, depth of chest wall involvement, and type of operative procedure did not 
significantly influence survival. 
The use of postoperative radiotherapy had no statistically significant effect on 
survival in our series, neither for patients who underwent en bloc resection nor 
for those who had extrapleural dissection. 
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Figure 2.2 Estimated survival following complete resection with (N1 - - -, N2 — - —) and without 
(N0 ——) lymph node involvement. + = censored cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Estimated survival following complete resection with (- - - ) and without (——) 
intrapleural tumour spill. + = censored cases. 
 
 
According to the multivariate analysis, sex, intrapleural tumour spill, and 
mediastinal lymph node involvement were identified as prognostic factors (Table 
2.4). 
Local recurrence of malignancy was found in 13 of 83 hospital survivors who 
underwent complete resection (15.7%), eight after en bloc resection, and five 
after extrapleural dissection. 
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Table 2.4. Proportional hazards regression model based on 83 patients with complete resection 
Variable ß SE Hazard ratio 95% CI 
Sex*  0.78 0.38 2.17 1.04 to 4.53 
Tumour spill** -1.51 0.36 0.22 0.11 to 0.44 
pTNM†  0.14 0.30 1.15 0.64 to 2.07 
pTNM††  0.89 0.26 2.43 1.45 to 4.08 
ß=regression coefficient; SE=standard error; CI=confidence interval; *=men versus women; **=no 
versus yes; †=pT3N1M0 versus pT3N0M0; ††=pT3N2M0 versus pT3N0M0 
Discussion 
In this study the overall hospital mortality of 3.2% is similar to the results of 
McCaughan et al.3, but lower than other reports.6,7,12-15 En bloc resection had no 
higher mortality rate (1.9%) than extrapleural dissection (4.1%). Our estimated 
mean 5-year survival for 121 hospital survivors of 24% is similar to the results of 
others5-7,12, but less than those achieved by Patterson et al.13 and McCaughan et 
al.3 The retrospective nature of our study sometimes made it difficult to trace 
former treatment strategies. 
The choice of extrapleural dissection or en bloc resection is an important factor 
in the treatment of lung cancer with chest wall invasion. Some authors favour en 
bloc resection of the carcinoma and chest wall5,6,14, whereas others have found 
no difference between the two procedures.3,7,12 However, comparison of these 
studies is difficult because of differences in patient selection, operative 
procedures, and statistical analysis. In this series there was no difference in 
mean 5-year survival between patients undergoing en bloc resection or 
extrapleural dissection when only the parietal pleura was involved. When 
invasion of the thoracic wall was proven pre-operatively by pathological 
examination en bloc resection was planned, otherwise the choice of operative 
procedure was made peroperatively. When the parietal pleura could be easily 
dissected from the ribs an extrapleural dissection was carried out, but when 
there was fixation of the tumour to the thoracic wall or when pathological 
examination showed positive resection margins en bloc resection was 
performed. However, 6 patients had positive resection margins at the parietal 
pleura although the surgeon was certain during the operation that all tumour 
was removed. This indicates that pathological examination of resection margins 
should always be carried out peroperatively and that, if there is any doubt about 
complete resection, an en bloc resection should performed, whenever possible. 
As is generally recognized, mediastinal lymph node involvement indicates an 
unfavourable prognosis.3,5-7,12-15 Mean 5-year survival for patients with N0 
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tumours was 36%, compared with 23% and 14% for N1 and N2 tumours, 
respectively. The difference between N0 and N2 tumours was statistically 
significant. 
The tumour was opened peroperatively in 7 patients and none of these patients 
lived more than 16 months. The difference in mean 5-year survival between 
patients with and without intrapleural tumour spill was significant (0% and 32% 
respectively). In our study, these 7 patients were judged to have had a complete 
resection but, because of their poor prognosis, we believe that intrapleural 
tumour spill must be regarded as incomplete resection. 
Histological examination showed a higher incidence of squamous cell 
carcinoma (55.2%). Patients with adenocarcinoma had a better mean 5-year 
survival than those with squamous cell carcinoma (40% and 26%, respectively), 
although the difference was not significant. The fact that adenocarcinomas are 
often located more peripherally and thus cause earlier complaints of chest pain 
may be a reason for this difference in survival. 
Unlike McCaughan et al.3, other studies reported no relation between depth of 
chest wall invasion and survival7,15 and our results are in agreement with this 
finding. Patients who underwent en bloc resection had no difference in mean 5-
year survival when there was tumour involvement in or beyond the parietal 
pleura. 
The indications for radiotherapy in resected T3 lung cancer with chest wall 
involvement remain unclear. Some authors13,16 have described a better survival 
in patients who have radiotherapy, while others have reported no 
difference.5,15,17 In this study preoperative radiotherapy was only given to 3 
patients so we can not comment on its efficacy. Sixty patients received 
postoperative radiotherapy, 27 of whom underwent incomplete resection and 33 
complete resection. In the latter group no significant relationship was found 
between survival and postoperative radiotherapy, but it must be borne in mind 
that this is a non-randomised series.  
No relationship was found between operative procedure and local recurrence. 
Thirteen patients who underwent complete resection had local recurrence: 
compared with five patients after extrapleural dissection and eight after en bloc 
resection. 
We conclude that complete resection in patients with T3 lung cancer involving 
the chest wall yields good survival results after either en bloc resection or 
extrapleural dissection. Both surgical techniques can be performed safely and 
invasion of the parietal pleura is not a contra-indication to extrapleural 
dissection. 
Mediastinal lymph node involvement, incomplete resection, and intrapleural 
tumour spill, however, imply an unfavourable prognosis. Postoperative 
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irradiation, age and depth of chest wall invasion do not influence survival 
significantly. 
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Abstract 
Background 
T3 tumours can be divided into several subgroups. Surgical 
treatment of T3 tumours with chest wall invasion results in good 
survival. This study shows the results of resection of T3 non-small 
cell tumours located in the main bronchus or with invasion of 
mediastinal structures. 
 
Methods 
From 1977 through 1993, 108 patients underwent resection for 
primary non-small cell carcinomas located in the main bronchus 
or with invasion of mediastinal structures. A complete resection 
was performed in 70 patients (64.8%). Actuarial survival time 
was estimated and risk factors for late death were identified. 
 
Results 
Overall hospital mortality was 8.3%. All deaths followed 
pneumonectomy. Mean 5-year survival was 29% for all hospital 
survivors, 35% for patients with complete resection, and 18% for 
patients with incomplete resection (p=0.03). In patients with 
complete resection, mean 5-year survival was 45% for N0 
patients and 37% for N1 patients. There were no 5-year survivors 
in the group of N2 patients. The mean 5-year survival was better 
(but not statistically significantly better) in patients with tumours 
located in the main bronchus (40%) than in patients with tumours 
with invasion of mediastinal structures (25%) (p>0.05). Histology, 
tumour spill, age, sex, and type of operative procedure were not 
significant prognostic factors. 
 
Conclusion 
Patients with tumours located in the main bronchus have a better 
survival than patients with invasion of the mediastinal structures. 
Pneumonectomy increases hospital mortality. Incompleteness of 
resection and mediastinal lymph node involvement influence 
survival significantly. 
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Introduction 
Pulmonary resection is the treatment of choice for non-small cell bronchogenic 
carcinoma if there are no distant metastases. Resectability is closely related to 
the stage of the disease.1 Whereas stage I and stage II tumours are considered 
to be resectable2, the role of resection for stage III tumours remains 
controversial. 
Stage III tumours can be divided into stage IIIA and stage IIIB tumours. Stage IIIA 
tumours include tumours with limited extrapulmonary extension of the primary 
tumour, like invasion of the superior sulcus, chest wall, mediastinal structures, 
pericardium, or diaphragm, or tumours with endobronchial proximity to the 
main carina. According to the TNM classification, these tumours are staged as 
T3.3 
Resection shows good survival results in bronchogenic carcinoma involving the 
chest wall.4,5 Our previous study6 was in agreement with these findings. 
The present report concerns 108 patients who underwent resection because of 
T3 tumours with invasion of the mediastinal structures, pericardium or with 
localisation in the main bronchus. It is a retrospective study to analyse survival 
characteristics. 
Patients and methods 
From 1977 to 1993, 2009 patients with bronchogenic carcinoma had a 
resection at our hospital. Of this group, 108 patients (5.4%) underwent 
operation for T3 non-small cell bronchogenic carcinoma with invasion of the 
mediastinal structures or pericardium, or localisation in the main bronchus at 
pathologic examination. Patients with distant metastases, synchronous tumours, 
and recurrences were excluded. Resection was considered as complete when (1) 
the surgeon was morally certain that all known disease was removed, (2) 
resection margins were free at pathological examination, and (3) the highest 
mediastinal lymph node was negative by microscopy. Peroperative tumour spill 
was scored separately. 
Ages ranged from 31 to 82 years with a mean of 60 years. One hundred and 
three patients were male and 5 were female. Ninety-eight patients (91%) were 
smokers. 
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The most common complaints were cough (75%), dyspnoea (47.2%), 
haemoptysis (39.8%), weight loss (27.8%), thoracic pain (25%), and hoarseness 
(12%). Sixteen patients (14.8%) presented without symptoms. 
A pre-operative diagnosis was obtained in 105 patients (97.2%). Bronchoscopy 
was diagnostic in 99 patients, and percutaneous needle aspiration biopsy of the 
lung and sputum cytology were diagnostic in 3 patients each.  
Fifty-seven tumours were located on the right side and 51 tumours on the left 
side. Cervical mediastinoscopy was negative in 98 patients (90.7%) and positive 
in 5 (4.6%). The latter group was operated on because they only had a positive 
lymph node at the ipsilateral tracheobronchial angle (n=3) or because they 
were relatively young (51 and 56 years) (n=2). The type of resection and tumour 
localisation are shown in Table 3.1. A complete resection was achieved in 70 
patients (64.8%), 46 patients with localisation in the main bronchus, 21 patients 
with involvement of the mediastinal structures, and 3 patients with localisation in 
the main bronchus and invasion of the mediastinal pleura. Resections were 
incomplete due to positive resection margins (87%) and positive lymph nodes 
(13%). A combined heart-lung operation was performed in 2 patients; 1 patient 
had a pneumonectomy and a coronary artery revascularization and 1 patient 
had a pneumonectomy and an aortic valve replacement. Four patients had a 
pneumonectomy and a tracheobronchial reconstruction because of positive 
resection margins. Peroperative tumour spill occurred in 5 patients (4.6%). 
The histologic diagnosis was squamous cell carcinoma in 90 patients (83.3%), 
adeno-squamous cell carcinoma in 8 patients (7.4%), adenocarcinoma in 5 
patients (4.6%) and large cell carcinoma in 5 patients (4.6%). 
 
Table 3.1.  Operative procedures and tumour localisation in 108 patients 
Procedure All patients 
(n=108) 
Patients with complete resection 
(n=70) 
Main bronchus   
    Pneumonectomy  61  42 
    Sleeve lobectomy  6  4 
    Lobectomy  1  0 
Mediastinal structures   
    Pneumonectomy  21  14 
    Bilobectomy  1  0 
    Sleeve lobectomy  3  1 
    Lobectomy  8  6 
Main bronchus and mediastinal structures   
    Pneumonectomy  7  3 
 
 
 Centrally located T3 NSCLC  45 
All patients were staged as T3 because of involvement of the mediastinal 
structures or pericardium, or localisation in the proximal airway (Table 3.2). In 3 
patients with a tumour located in the main bronchus, there was also atelectasis 
of the complete lung. The pericardium was involved in 8 patients. Of these 
patients, 5 patients had also tumour involvement of the phrenic nerve. An 
intrapericardial pneumonectomy was performed in 6 patients, which was 
complete in 4 patients. Two patients had a lobectomy and partial 
pericardiectomy. 
 
Table 3.2.  Structures involved in T3 tumours* 
Structure Number of patients 
Main bronchus within 2 cm of the carina   75 
Mediastinal pleura  32 
Phrenic nerve  10 
Pericardium  8 
* Involvement of more structures at the same time was possible 
 
 
Pathologic TNM classification is shown in Table 3.3. One patient was staged as 
T3N0M1 because of a metastasis on the pericard. He underwent an incomplete 
pneumonectomy. 
 
Table 3.3. Pathologic TNM classification and tumour localisation of all patients and patients with 
complete resection 
pTNM All patients 
(n=108) 
Patients with complete resection 
(n=70) 
Main bronchus   
 pT3N0M0  13  12 
 pT3N1M0  38  28 
 pT3N2M0  17  6 
Mediastinal structures   
 pT3N0M0  11  6 
 pT3N1M0  16  13 
 pT3N2M0  6  2 
Main bronchus and mediastinal structures   
 pT3N0M0  1  1 
 pT3N0M1  1  0 
 pT3N1M0  2  2 
 pT3N2M0  3  0 
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Thirty-five patients (32.4%) received irradiation as adjuvant therapy. Three 
patients (2.8%) were irradiated pre-operatively: 2 patients because of a large 
tumour and 1 patient because he was first suspected to have chronic lymphatic 
leukaemia. Thirty-two patients (29.6%) received radiotherapy postoperatively. Of 
these patients, 20 patients underwent an incomplete resection. In the group of 
patients with complete resection, 6 patients were irradiated because of positive 
mediastinal lymph nodes. 
Six patients (5.6%) received postoperative chemotherapy because of an 
incomplete resection. 
Follow-up was complete as of January 1995. Follow-up data were obtained 
from hospital files and from questionnaires to referring pulmonary physicians 
and general practitioners. Follow-up about local recurrence or distant 
metastases was achieved in 95.4 % of the patients. 
Survival was estimated from the date of operation, using the Kaplan-Meier 
survival analysis method.7 Hospital deaths were excluded. Survival comparisons 
were analysed by the log rank test.8 The difference was considered statistically 
significant when the p-value was less than 0.05. Incremental risk factors 
affecting survival were evaluated using Cox's proportional hazards model.9 
Results 
Hospital mortality was 8.3% (pneumonectomy 10.1% [9/89], lobectomy 0% 
[0/19]). Regarding the localisation of the tumour, hospital mortality was 8.8% 
(6/68) for tumours localized in the main bronchus, 3% (1/33) for tumours with 
involvement of mediastinal structures, and 28.6% (2/7) for tumours with 
involvement of the main bronchus and mediastinal structures. Six deaths were 
due to bronchopleural fistula in the postoperative period, one to sepsis, one to 
cardiac arrest, and one to adult respiratory distress syndrome.  
Of 6 patients with bronchopleural fistula, 5 had a tumour located on the right 
side and 1 on the left side. In all patients the bronchial stump had been covered 
with surrounding tissue. The operation was incomplete because of massive 
residual carcinomatous tissue at the bronchial stump in 1 patient. This was the 
only patient who had received pre-operative radiotherapy in whom a 
bronchopleural fistula developed. In another patient with a bronchopleural 
fistula the operation was incomplete because of positive mediastinal lymph 
nodes. In 4 patients sutures of 3-0 Vicryl (Ethicon, Somerville, NJ) were used to 
close the main bronchus. A stapler was used in the remaining 2. For patients 60 
years of age or younger, hospital mortality was 7.0% (4/57), compared with 
9.8% (5/51) for those older than 60 years.  
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Estimated mean 5-year survival was 27% for all patients (n=108) and 29% for 
hospital survivors (n=99). 
Complete resection was performed in 64 hospital survivors (64.6%) with a mean 
5-year survival of 35%. The remaining 35 hospital survivors underwent an 
incomplete resection with a mean 5-year survival of 18% (p=0.03) (Figure 3.1). 
Because of this significant difference in survival between patients with complete 
and incomplete resection, only the results of hospital survivors with complete 
resection were studied for the analysis of other prognostic factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Estimated survival in patients with complete resection (——) and incomplete resection  
 (- - -). + = censored cases. 
 
Regarding lymph node involvement, mean 5-year survival was 45% for N0 
patients, and 37% and 0% for N1 and N2 patients, respectively. The difference 
between N0 and N1 disease versus N2 was statistically significant, with a p-
value of 0.03 and 0.02, respectively (Figure 3.2). 
Regarding T3 classification, mean 5-year survival of hospital survivors with 
tumour localisation in the main bronchus within 2 centimetres of the carina was 
40%. Mean 5-year survival of hospital survivors with tumour involvement of the 
adjacent mediastinal structures was 25%. The difference between the two groups 
was not statistically significant. 
Patients with squamous cell carcinoma had a better mean 5-year survival than 
patients with adenocarcinoma, adeno-squamous cell carcinoma, or large cell 
carcinoma, but the difference was not statistically significant (37% and 22%, 
respectively, p=0.31). 
In the group of patients with complete resection, postoperative radiotherapy did 
not improve survival. On the contrary, mean 5-year survival of patients who 
years after resection 
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received radiotherapy was 17%, whereas patients who were not irradiated had a 
mean 5-year survival of 39% (p=0.01) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Estimated survival after complete resection with lymph node involvement (N1 — —,  
 N2 - - -) and without lymph node involvement (N0 ——). + = censored cases. 
 
Patients younger than 60 years had a better survival than older patients (38% 
and 31%, respectively). This difference was not significant, but when a new 
classification into patients younger than 70 years and older was made, the 
difference was of borderline significance (p=0.05). Sex, tumour spill, and type 
of operative procedure did not influence survival significantly. 
According to the multivariate analysis regarding age, sex, pTNM classification, 
histology, localisation and tumour spill, only mediastinal lymph node 
involvement was a significant prognostic factor (Table 3.4).  
Distant metastases developed in 25 of 64 hospital survivors with complete 
resection (39.1%) and 8 patients had local recurrence (12.5%). One patient had 
combined local and distant recurrence (1.6%). 
 
Table 3.4. Proportional hazards regression model based on 64 patients with complete resection 
Variable ß SE Hazard ratio 95% CI 
pTNM* 0.31 0.37 1.36 0.66-2.81 
pTNM** 1.21 0.50 3.35 1.25-8.99 
ß=regression coefficient; SE=standard error; CI=confidence interval; *=pT3N1M0 versus 
pT3N0M0; **=pT3N2M0 versus pT3N0M0 
cu
m
ul
at
iv
e 
su
rv
iv
al
 
years after resection 
 Centrally located T3 NSCLC  49 
Comment 
Surgical treatment of non-small cell bronchogenic carcinoma is closely related to 
the stage of the disease.1 Some selected T3 tumours are potentially resectable. 
Patients with bronchogenic carcinoma involving the thoracic wall have good 
survival rate when a complete resection is performed and there are no 
mediastinal metastases.4,5 Similar results have been published about tumours 
located in the main bronchus.10-14 Although some studies about tumours 
invading the mediastinum have been published15-18, the role of resection for 
carcinomas invading the mediastinal structures remains unclear.  
The present study was undertaken to analyse survival characteristics of patients 
with T3 tumours in the main bronchus or with invasion of mediastinal structures. 
Comparison with other reports is sometimes difficult due to differences in patient 
selection, tumour invasion, operative procedure, and statistical analysis.  
Hospital mortality was 8.3%. It was closely related to type of operation: 
pneumonectomy had a higher hospital mortality (10.1%) than lobectomy (0%). 
This concurs with the results of others.11,12 Although hospital mortality is high, 
mean 5-year survival of complete resection by pneumonectomy is still 37%. 
Mortality was particular high in patients with a tumour with carinal proximity 
(8.8%) in contrast to patients with a tumour invading mediastinal structures (3%). 
Our findings agree with the results published, where hospital mortality for 
tumours with carinal proximity varies between 6% and 11%10-12, whereas 
tumours invading mediastinal structures have a hospital mortality of 3% to 
6%16,18, although it must be noticed that this study included more 
pneumonectomies in the group of patients with a tumour in the main bronchus. 
An important source of postoperative problems was a bronchopleural fistula 
which developed in 7 patients. Six of them died in the postoperative period. In 
literature the prevalence of bronchopleural fistula ranged from 2% to 10%.19 
Operative mode (pneumonectomy with bronchoplasty), residual carcinomatous 
tissue at the stump, preoperative radiotherapy, and diabetes mellitus are 
significant risk factors.19 In this study, all patients with bronchopleural fistula had 
a pneumonectomy and a tumour located in the main bronchus. This stresses the 
importance of surgical technique in this type of tumour. Only 1 patient was 
irradiated pre-operatively and had positive resection margins at the bronchus 
stump. Although age is often correlated with operative mortality, no significant 
correlation was found in this study. 
The estimated mean 5-year survival for 99 hospital survivors was 29%. This is 
similar to the results of others.12,13,18 In patients with complete resection the 
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mean 5-year survival was 35%, whereas patients with an incomplete resection 
had a mean 5-year survival of 18%. 
Regarding the localisation of the tumour, patients with bronchogenic carcinoma 
located in the main bronchus had a better mean 5-year survival (40%) than 
patients with a tumour invading mediastinal structures (25%), although the 
difference was not statistically significant. This was also described by Nakahashi 
and associates15, who found a 4-year survival of patients with invasion of the 
main bronchus of 80%, demonstrating that this subcategory of T3 tumours had 
a favourable prognosis. 
Based on the promising results of chemotherapy in patients with N2 tumours, 
the use of induction chemotherapy or chemoradiotherapy before resection 
becomes relevant in bronchogenic carcinoma involving mediastinal structures to 
improve completeness of resection and survival. 
Like other reports15,16,20, mediastinal lymph node involvement had a poor 
prognosis. In this study, no patient with mediastinal lymph node involvement 
survived more than 5 years. 
Histologic analysis showed no statistically significant difference in mean 5-year 
survival between patients with squamous cell carcinoma and adenocarcinoma, 
adenosquamous cell, or large cell carcinoma, although the first patient group 
had a better mean 5-year survival (37% versus 22%). This is also described by 
others17,20, although Martini and associates18 found a better survival for patients 
with adenocarcinoma. 
Patients with complete resection who received postoperative radiotherapy had a 
worse survival than patients who were not irradiated (17% versus 39%). A 
possible reason for this difference is the fact that 50% (6/12) of patients with 
complete resection who received radiotherapy had N2 disease, which is 
associated with a poor prognosis.  
Comparing the results of this study with the results of complete resection of T3 
bronchogenic carcinoma involving the chest wall6, patients with a tumour 
located in the main bronchus had the best prognosis, but the difference was not 
statistically significant (mean 5-year survival was 40% and 29%, respectively). 
In conclusion, complete resection in patients with invasion of mediastinal 
structures shows moderately good results, whereas patients with involvement of 
the main bronchus have a superior survival rate. Mediastinal lymph node 
involvement worsens the prognosis significantly. 
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Summary 
Due to its localisation in the apex of the lung with invasion of 
the lower part of the brachial plexus, first ribs, vertebrae, 
subclavian vessels or stellate ganglion, a superior sulcus 
tumour causes characteristic symptoms, like arm or shoulder 
pain or Horner’s syndrome. If rib invasion is the only feature, 
lyses of the rib must be evident on the chest radiograph, 
otherwise the tumour can not be defined as a Pancoast tumour. 
It is important to adequately stage the tumour, because staging 
significantly influences survival. Survival is better for T3 than T4 
tumours and mediastinal lymph node involvement has been 
found to be a negative prognostic factor. Also Horner’s 
syndrome and incompleteness of resection worsen survival. 
The management of superior sulcus tumours has evolved over 
the past 50 years. 
Before 1950 it was considered to be inoperable and uniformly 
fatal. Shaw and Paulson introduced combined modality 
treatment and for many years, this combination of radiotherapy 
and surgery was the treatment of choice with a mean 5-year 
survival of approximately 30%. Postoperative radiotherapy or 
brachytherapy does not improve survival in patients with 
complete or incomplete resection. The tumour can be resected 
through the classic posterior Shaw-Paulson approach or the 
newer anterior transcervical approach, introduced by 
Dartevelle. This method facilitates better exposure of the 
extreme apex of the lung, brachial plexus and subclavian 
vessels. Regarding the extent of pulmonary resection, en bloc 
resection of the involved ribs with a lobectomy is 
recommended. 
Recent multimodality studies, involving chemoradiotherapy and 
surgical resection, show promising results regarding 
completeness of resection, local recurrence and survival, 
provided that appropriate staging has been carried out.  
However, careful patient selection and adequate perioperative 
management with protection of the bronchial stump or 
anastomosis are important to achieve reasonable rates of 
morbidity and mortality.  
As brain metastases remain one of the most common forms of 
relapse, further studies are needed to examine the role of 
prophylactic cranial irradiation in patients with complete 
resection. Also the addition of other chemotherapy agents or 
biologic agents such as angiogenesis inhibitors or tyrosine 
kinase inhibitors gives a new perspective in the treatment of 
Pancoast tumours. 
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Introduction 
Pancoast or superior sulcus tumours produce a characteristic clinical syndrome, 
which was first described by Edwin Hare in 1838.1 In 1924 Henry Pancoast, 
radiologist, called this tumour, located in the apex of the lung and associated 
with typical complaints “apical chest tumour”. In 1932 he changed this name in 
superior sulcus carcinoma.2,3 His first impression was that the tumour was 
extrapulmonary of origin, arising from epithelial remnants of the fifth branchial 
cleft. However, Tobias recognised that its origin was bronchopulmonary tissue 
and that it was the localisation of the tumour that made it specific and not its 
origin.4 Pancoast’s – Tobias syndrome is a constellation of characteristic 
symptoms that includes pain down the arm and eventually weakness and 
numbness along the distribution of the eight cervical nerve trunk and first and 
second thoracic nerve trunks, Horner’s syndrome, and radiographic evidence of 
destruction of the first thoracic rib or vertebral body. It is caused by benign or 
malignant tumours invading portions of the lower brachial plexus, subclavian 
vessels, vertebral bodies, parietal pleura, apical ribs and the stellate ganglion.2,3 
The tumour represents less than 5% of all bronchogenic carcinoma and recent 
reports indicate that its biology is not different from the usual non-small cell lung 
tumours with its predilection for distant metastases.5-8 Although Pancoast’s 
syndrome may be the result of different neoplastic, inflammatory, and infectious 
diseases, the focus of this review will be on the clinical presentation, diagnosis, 
and treatment of primary non-small cell bronchogenic carcinoma, which causes 
the vast majority of cases. We will also present the results of surgical treatment 
of 24 patients who underwent a resection in our hospital because of a superior 
sulcus tumour. 
Clinical presentation and diagnosis 
Superior sulcus tumours may occur in three locations and symptoms are related 
to the location: anterior, in which they invade major blood vessels such as the 
subclavian artery; middle, in which they mainly invade the brachial plexus; and 
posterior, in which they invade the stellate ganglion or vertebral bodies. In case 
of invasion of the brachial plexus, patients often present with pain that begins in 
the shoulder and scapular region and then extends down to the ulnar aspect of 
the arm (T1 dermatome) onto the small and ring fingers (C8 dermatome). This 
pain can be very intensive and often patients are first submitted to the 
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physiotherapist and neurologist or orthopaedist. With increasing pressure on the 
nerve roots, muscle atrophy of the ulnar aspect of the hand and loss of the 
triceps reflex can occur. Because of these aspecific complaints, the time between 
onset of the symptoms and a correct diagnosis is around 6-10 months.9-11 In 
about 20% of the patients tumour invasion of the sympathetic chain and the 
stellate ganglion causes Horner’s syndrome (ipsilateral ptosis, miosis, and 
anhydrosis). 
Specific pulmonary symptoms like cough, dyspnoea, and haemoptysis are 
mostly absent in the initial stages of the disease due to the peripheral 
localisation of the tumour. A pathological diagnosis is often difficult to obtain by 
fiberoptic bronchoscopy.9,12 The most sensitive procedure for diagnosis is a 
percutaneous transthoracic needle biopsy with a diagnostic yield of 95%.9,13,14 
On a chest roentgenogram, the tumour is visible as a small mass or pleural 
thickening in the apex of the lung with rib and possible vertebral body invasion, 
although the tumour can be easily missed on a regular chest X-ray. The apical 
lordotic or slightly oblique views show the apical lesions much better. Computed 
tomography (CT) and nowadays magnetic resonance imaging (MRI) are the 
preferred imaging modality for these tumours because they visualise best the 
relationship of the tumour to adjacent structures like the brachial plexus, 
subclavian vessels and vertebral bodies.15 
Regarding histology, non-small cell lung cancer accounts for 90 to 95% of the 
cases. In current reports, adenocarcinoma is the most common histological 
diagnosis, followed by squamous cell carcinoma and large cell carcinoma.16,17 
Small cell carcinoma is only rarely associated with this syndrome.11,18 The 
differential diagnosis of Pancoast’s syndrome includes other primary thoracic 
neoplasms (mesothelioma, lymphoma, plasmacytoma), infectious processes with 
organisms such as actinomyces, staphylococcus and echinococcus, neurogenic 
thoracic outlet syndromes and pulmonary amyloidosis.7 This wide variety of 
diseases makes it necessary to make a definitive diagnosis before treatment is 
started. After the diagnosis of a Pancoast tumour is confirmed, it is important to 
adequately stage the tumour. 
Staging and survival 
Because of involvement of the chest wall, these carcinomas are at least staged 
as T3. Invasion of the vertebral body, or the subclavian vessels upgrades the 
staging to T4. Staging significantly influences survival. In the study of Rusch and 
associates actuarial 5–year survival was 46% for stage IIB (T3N0) and 13% for 
stage IIIB.19 Both univariate and multivariate analysis showed that T and N status 
had a significant impact on survival. 
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In the study of Ginsberg and colleagues, of 22 patients with vertebral body 
invasion, only 2 survived for 5 years.17 Other studies support the poor prognosis 
associated with vertebral body invasion.14,16 Also tumours with invasion of the 
subclavian vessel are staged as T4. Dartevelle and co-workers, using the 
anterior transcervical-thoracic approach, have reported a 30% actuarial 5-year 
survival in 12 patients.20 In most studies, however, subclavian vessel involvement 
is a negative prognostic factor.14,16,17 
Lymph node status is a very important prognostic factor.16,21 In the past, 
mediastinoscopy was not routinely performed in most studies. Because patients 
with mediastinal lymph node metastases exhibit poor survival, most surgical 
groups nowadays recommend staging of the mediastinum by mediastinoscopy 
or positron emission tomography (PET) scan to document the absence of N2 
disease, even if the CT or MRI do not demonstrate enlarged lymph nodes.6,7,22,23 
Some series show that patients with supraclavicular lymph node metastases had 
a better prognosis than patients with N2 disease. Ginsberg and associates found 
a 5-year survival of 14 % in patients with N3 disease as opposed to 0% in 
patients with N2 disease.17 Comparable results were described by Hilaris and 
co-workers21, suggesting that tumour involvement of these nodes does not 
necessarily exclude a curative resection because, in the context of a Pancoast 
tumour, this form of disease simply represents local contiguous spread.6 
To exclude metastatic disease, a CT of the liver and adrenal glands or PET scan 
should be performed. As brain metastases are the most frequent form of distant 
metastases, the question rises if all patients should have a CT or MRI of the 
head.7,24 Bone scans are mostly performed only if indicated by the patient’s 
symptoms. 
Treatment and results 
The management of superior sulcus tumour has evolved over the last decades 
and has consisted of surgery alone, radiotherapy alone, pre-and postoperative 
radiotherapy, or most recently, preoperative chemoradiation.6,25-27 
Before 1950 the tumour was considered to be inoperable and uniformly fatal. 
Heburt and Watson reported survival without treatment between 3 and 24 
months.28 In 1953 Chardack and MacCallum reported the first 5-year survival in 
a patient who initially underwent resection followed by 65 Gy of radiation.29 
Subsequently, Shaw presented a series of 18 patients who were treated by 
preoperative radiotherapy followed by en bloc resection with up to 51 months 
survival.30 And for many years, this combination of radiotherapy and surgery 
was the treatment of choice. 
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Radiotherapy alone 
Radiotherapy was initiated by Haas and associates in patients with otherwise 
hopeless thoracic neoplasms. This treatment resulted in good pain relief and 
improvement of survival.31 In 1950, Binkley reported the first cure using 
interstitial brachytherapy.32 
The doses of radiotherapy used usually ranges between 50 to 70 Gy. In most 
studies, long-term survival rates are low.33 This is particularly due to the fact that 
these studies often include patients with advanced disease and poor 
performance status. In selected patients, 5-year survival is about 20%, but these 
results cannot be compared with those of surgical series because of differences 
in patient selection.18,33-35 
Combined modality: radiotherapy and surgery 
The combination of preoperative radiotherapy with doses between 30 and 35 
Gy followed by surgical resection was first reported by Shaw and his colleagues 
in 1961.30 Paulson and associates used this approach, updated it on several 
occasions and found that preoperative radiation including the primary tumour, 
mediastinum and supraclavicular region facilitated surgical resection and that 
combined treatment was potentially curative. In their series overall 5-year 
survival was 31% and for patients with no nodal involvement 44%.36 In most 
studies, 5 year survival ranges between 10% and 56% (Table 4.1). Patients with 
a complete resection had improved 5-year survival rates of 40%.11,17,37 Results of 
preoperative radiotherapy followed by surgery in 225 patients in the Memorial 
Sloan-Kettering Cancer Center published by Rusch and colleagues showed that 
a complete resection was achieved in only 64% of T3N0 and 39% of T4N0 
tumours. Five-year survival was 46% for stage IIB, 0% for stage IIIA and 13% for 
stage IIIB. Locoregional disease was the most common form of relapse (40%).19 
Usually, the dose of preoperative radiotherapy ranged between 30 and 35 Gy. 
Because of a well known dose-response curve in patients with non-small cell 
lung cancer which suggests that standard treatment is in the range of 50 to 60 
Gy, Attar and Miller gave preoperative doses of radiotherapy of 40 to 60 
Gy.33,38 However, both groups noticed an increase of postoperative morbidity 
and mortality and so lowered the dose to 30 Gy. Fuller and Chambers also used 
as much as 60 Gy preoperatively, but their study showed no survival 
advantage.37 No large phase II or III trials have been reported testing the 
standard approach of induction radiotherapy in patients with superior sulcus 
tumours. 
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Table 4.1. Preoperative radiotherapy followed by surgical resection for patients with superior 
sulcus tumours 
First author  (year) No. of patients Complete resection 
(%) 
5-year survival 
 (%) 
Attar33  (1979)  19 NS  23 (3-year) 
Paulson36  (1985)  78 NS  31 
Devine35  (1986)  40 NS  10 
Shahian39  (1987)  18 50  56 
Wright14  (1987)  21 76  27 
Hilaris21  (1989)  82 NS  29 
Sartori16  (1992)  42 NS  25 
Ginsberg17  (1994)  124 56  26 
Maggi11  (1994)  60 60  17.4 
Attar25  (1998)  28 NS  27 
Hagan8  (1999)  34 NS  33 
Dartevelle44  (1999)  70 NS  35 
Pitz  (2004)  18 33.3  16.7 
NS= not stated 
 
 
The potential benefits of preoperative radiotherapy include a decrease in the 
size of the tumour, with improved resectability, and a reduction in the number of 
viable cells, which theoretically prevents dissemination of the tumour during 
surgery.30,36 Surgery is usually performed 2 to 4 weeks after the last radiation. 
Shahian and colleagues reported on 18 patients who were treated with 
preoperative radiotherapy. 14 of these patients also received postoperative 
radiotherapy because of N2 disease, positive resection margins, or both. 
Overall 5-year survival was 56%. They believed that this “sandwich” radiation 
would improve survival.39 Ginsberg also reported 4 long-term survivors in a 
group treated with sandwich radiotherapy, but too few patients have received 
this treatment to assess its outcome and radiobiologically it is not 
recommended.17 
The rates of complete resection with preoperative radiotherapy followed by 
resection have not changed in the last past years (Table 4.1). Any apparent 
increased survival has probably occurred because of better patient selection due 
to enhanced detection of unresectable disease or occult metastatic disease with 
modern radiological imaging. 
The role of intra-operative and postoperative radiotherapy is unclear at this 
time, but most studies have failed to demonstrate any advantage regarding 
survival for postoperative radiotherapy or intra-operative brachytherapy in the 
face of incomplete resection or N2 disease. Same results were described in 
patients with complete resections.17,21,37 
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Surgical technique 
Surgical resection remains the treatment of choice for superior sulcus tumours. 
The goal is to resect the upper lobe with the invaded ribs and transverse 
processes and all invaded structures such as the lower trunk of the brachial 
plexus, stellate ganglion and upper dorsal sympathetic chain. The problem is 
that the apex is a small, rigid, bone encased area which is difficult to access and 
that surrounding structures are either difficult to resect macroscopically free of 
tumour (vertebrae) or that resection can leave important deficits (brachial plexus, 
subclavian vessels). In patients with involvement of the brachial plexus or the 
spine, a combined thoracic, orthopaedic and neurosurgical approach can 
improve resectability and local control.40 
Different surgical approaches have been described. As a general rule, superior 
sulcus tumours not invading the thoracic inlet are completely resectable through 
the classic posterior Shaw-Paulson approach.30 This consists of a posterolateral 
thoracotomy with a high posterior parascapular incision carried to the base of 
the neck. This method allows good access to the posterior part, but poorer 
access to the more anterior structures like the subclavian vessels. Chest wall 
reconstruction is rarely needed because the defect is covered by the scapula. A 
newer alternative approach is the anterior transcervical approach, popularized 
by Dartevelle and colleagues.20 This method facilitates better exposure of the 
extreme apex of the lung and cervically based structures (brachial plexus and 
subclavian vessels). The incision parallels the lower sternocleidomastoid muscle 
and courses over the manubrium and then turns laterally below the involved 
clavicle. Resection, division or retraction of the clavicle opens the thoracic inlet. 
This approach shows lower morbidity than the posterior approach because the 
posterior chest wall muscles and the shoulder are undisturbed. However, these 
osteomuscular resections can cause postoperative alterations in the shoulder 
mobility and cervical posture. To avoid these deformities Grunenwald and 
colleagues developed a transmanubrial technique, through a manubrial L-
shaped transaction and first costal cartilage resection, which allows retraction of 
an osteomuscular flap including but sparing the clavicle and its muscular 
insertions.41 Recently, both Dartevelle and Grunenwald developed a technique 
which is a combination of a transcervical or transmanubrial and posterior 
midline approach. This technique makes it possible to resect posteriorly located 
superior sulcus tumours extending into the intervertebral foramen without 
intraspinal extension.40,42,43 
Regarding the extent of pulmonary resection, a lobectomy is recommended.17,23 
Ginsberg and associates reported a survival benefit (lobectomy 60% versus 
limited resection 33%) and a reduction in local recurrence in patients who 
underwent a lobectomy.17 
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The reported surgical morbidity ranges from 7 to 38% with surgical mortality 
generally around 5 to 10%.9,16,21 Surgical complications include spinal fluid 
leakage, Horner’s syndrome and nerve deficits, haematothorax, chylothorax and 
prolonged ventilatory support. The postoperative course is usually characterized 
by atelectasis because of the concomitant extended chest wall resection and 
phrenic nerve resection. 
Invasion of the subclavian vessel is a relative contraindication, but successful 
surgical resection has been described.14,20 Absolute surgical contraindications 
are the presence of extrathoracic metastases, mediastinal lymph node 
involvement, invasion of the brachial plexus above T1 as supported by sensitive 
or motor deficits in the nerve distribution of the median and radial nerves or 
vertebral body invasion with invasion of the spinal canal.44 
Own results 
Between 1977 and 1993, we operated on 24 patients (mean age 53.3 years, 
range 38 to 71 years) with superior sulcus tumours. The diagnosis was made by 
the clinical presentation of pain around the shoulder and upper arm, associated 
with a tumour in the apex of the lung. Duration of the symptoms before 
diagnosis ranged from 3 to 24 months. The majority of the lesions were either 
squamous cell carcinoma (n=11) or adenocarcinoma (n=11), 2 patients had a 
large cell carcinoma. pTNM classification was pT3N0M0 in 19 patients, 
pT3N1M0 in 2 patients, pT3N2M0 in 1 patient and pT4N0M0 in 2 patients. The 
patients were divided into 3 groups according to the method of therapy: group I 
(n=9) preoperative radiation and surgery, group II (n=6) surgery and 
postoperative radiation, group III (n=9) preoperative radiation followed by 
surgery and postoperative radiotherapy. Preoperative radiotherapy was 
delivered to the primary tumour and mediastinum and doses ranged between 
30 Gy and 50 Gy. The involved lung was resected by lobectomy in 18 patients 
and segment or wedge resections in 6 patients. The 6 patients in group II 
received postoperative radiotherapy to the tumour and mediastinum with doses 
between 55 to 60 Gy. 
Group III comprised 9 patients who had preoperative radiotherapy (range 30 to 
40 Gy) followed by surgery and postoperative radiation (range 20 to 30 Gy). 
A complete resection was only possible in 6 patients (25%). All these patients 
were treated with pre-operative radiotherapy. There were no hospital deaths. 
The median survival for all patients was 1.9 year. The 5-year survival rate was 
25%. The median survival for group I was 1.2 year, for group II 1.6 year and for 
group III 2.2 year. There was no statistical difference in survival between the 
groups. 
By univariate analysis age, sex and cell type were not statistically significant. 
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Induction chemoradiotherapy and surgery 
Because of the reported improved results of combined treatment with 
chemotherapy and irradiation in patients with stage IIIA and stage IIIB non-small 
cell lung cancer, it seemed logical to apply such therapy to patients with 
Pancoast tumours (Table 4.2). The combination of radiotherapy and radiation –
sensitizing chemotherapy increases the chance of performing a complete 
resection. At the current time concurrent treatment is favoured above sequential 
treatment, but concurrent chemoradiotherapy can be more toxic than sequential 
and requires close monitoring of the patient. 
 
Table 4.2.  Preoperative chemoradiotherapy followed by surgical resection for patients with 
superior sulcus tumours 
First author  (year) No. of patients Complete resection  
(%) 
4-year survival  
(%) 
Martinez-Monge45  (1994) 18 76 56 
Rusch26  (2001)  111 92 55, patients with 
CR* 70 (2-year) 
Wright46  (2002) 15 93 84 
*= complete resection 
 
Martinez-Monge and associates reported on a series of 18 patients with 
Pancoast tumours treated with cisplatin based chemotherapy followed by 
simultaneous preoperative chemotherapy and irradiation, after which the patient 
underwent resection with insertion of brachytherapy catheters. Resectability rate 
was 76.4% and a complete pathologic response was seen in 70.5%. Local 
failure rate was only 9% and 4-year actuarial survival was 56%. However, 
mortality was 16.7%.45 Same results were described by the Southwest Oncology 
Group which conducted a prospective phase II North America Intergroup study 
looking at preoperative chemoradiotherapy.26 This study included 111 patients 
with T3-4 superior sulcus tumours without mediastinal lymph node metastases. 
102 patients completed the induction treatment of 2 cycles of cisplatin based 
chemotherapy concurrent with 45 Gy of radiation. Of 95 patients eligible for 
surgery, 83 underwent a resection, which was complete in 76 (92%). Fifty-four 
patients (65%) had either a pathologic complete response or minimal 
microscopic disease. The 2-year survival was 55% for all eligible patients and 
70% for patients with a complete resection. Overall treatment mortality was only 
4.5%. Assessment of response to induction treatment was difficult. Only 40% of 
the patients with radiologically stable disease and 27% of the patients with a 
radiological partial response had significant gross residual tumour at 
thoracotomy. This shows that radiological response to induction treatment has to 
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be viewed with caution and usually underestimates the results of treatment. The 
intent of the study was to treat all patients with two additional cycles of the same 
chemotherapy regardless of whether a resection was performed, but in the 
postoperative group, this was only feasible in a small group of patients. 
Better results of combined chemoradiotherapy followed by surgery compared to 
induction radiation are also described by Wright and colleagues.46 However, 
surgery has to be considered a high-risk procedure after induction 
chemotherapy or chemoradiotherapy. Careful patient selection and adequate 
perioperative management with protection of the bronchial stump or 
anastomosis are important to achieve reasonable rates of morbidity and 
mortality.47,48 
At the moment, a prospective phase II intergroup trial (S0220) is being 
conducted by the Southwest Oncology Group. In this study, patients will receive 
induction chemoradiotherapy with cisplatin/etoposide and then go on to receive 
consolidation taxane cytotoxic chemotherapy in the postoperative setting which 
appeared to be effective even in tumours previously treated with or resistant to 
cisplatin.49 
Recurrence and prognostic factors 
Control of locoregional disease remains the major challenge in treating 
Pancoast tumours. Despite the relative improvement in survival of patients with 
superior sulcus tumours treated with combined preoperative radiotherapy and 
operation, there is still a high incidence of local recurrence between 25 and 
70%. In the study of Ginsberg of 69 patients with complete resection, two third 
of the cases had local recurrence.17 Most frequent sites are the spine, chest wall 
and lung.19 However, treatment with combined preoperative chemoradiation 
seems to lower this incidence of local recurrence.26,46 In the study of Rusch and 
associates, local recurrence was only 23%. This concurrent treatment appears to 
change the most common side of relapse from local to distant. Brain metastases 
are one of the most common forms of relapse, accounting for 40% to 80% of 
distant recurrences, especially in patients with poorly differentiated large cell 
carcinoma and adenocarcinoma.8,17,21 This raises the question whether patients 
with a complete resection should be treated with prophylactic cranial irradiation 
(PCI).21,26,34 In general, few studies have routinely used PCI in patients with non-
small cell bronchogenic carcinoma. Eberhardt and colleagues did not perform a 
randomised investigation of PCI in their study, but the overall brain relapse was 
remarkably reduced in the group that received PCI even though no impact on 
survival was noted.50 In the study of Stuschke and associates, regarding PCI in 
locally advanced non-small cell lung cancer after multimodality treatment, this 
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treatment reduced the rate of overall brain metastases from 54% to 13% 
(p<0.0001).51 Bone metastases appear to be to second most common side of 
distant disease.21,38 
Factors associated with poor prognosis are extension of the tumour into the 
basis of the neck, mediastinal lymph node involvement, invasion of vertebral 
bodies or great vessels, presence of Horner’s syndrome, and incompleteness of 
resection. The value of histology per se as a prognostic factor is 
controversial.7-9,17,19,36 
Conclusion 
After Shaw introduced combined modality treatment for patients with a superior 
sulcus tumour, this combination of preoperative radiotherapy followed by 
surgery was the treatment of choice with a mean 5-year survival of 
approximately 30%. In several studies, it appeared that N2 disease and 
incomplete resections had an adverse impact on survival and that postoperative 
radiotherapy or brachytherapy did not improve survival in patients with complete 
or incomplete resections. 
During the 1990s, studies have focused on prognostic factors and adequate 
staging, on determining the role of brachytherapy and on exploring new surgical 
techniques that facilitated complete resection. Despite these reports, complete 
resection rate and 5-year survival were low and locoregional recurrence 
remained the predominate form of relapse. 
These results emphasized the need for improved therapy for superior sulcus 
tumours. A multimodality approach, involving chemoradiotherapy and surgical 
resection shows promising results, provided that appropriate staging has been 
carried out. In the study of Rusch and colleagues cisplatin based chemotherapy 
with concurrent radiation followed by surgery is feasible and resectability and 
overall survival were improved. However, careful patient selection and adequate 
perioperative monitoring are very important, regarding the higher morbidity and 
mortality rates in some studies after induction chemotherapy.  
As brain metastases are one of the most common forms of relapse, the question 
rises whether patients with a complete resection should be treated with PCI. 
Given the proven efficacy of this treatment to prevent metastases to the brain in 
small cell lung cancer, the introduction of PCI into the treatment of non-small 
cell lung cancer in the curative setting seems promising.  
Another approach to diminish the incidence of distant metastases can be the 
addition of another chemotherapy agent, like docetaxel, or biologic agents such 
as angiogenesis inhibitors or tyrosine kinase inhibitors.  
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Therefore, further studies are needed to minimize morbidity and mortality and to 
examine the best combination of induction chemotherapy and biological agents 
and the role of prophylactic cranial irradiation. 
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Abstract 
Background 
Because of location and invasion of surrounding structures, the 
role of surgical treatment for T4 tumours remains unclear. 
Extended resections carry a high mortality and should be restricted 
for selected patients. This study clarifies the selection process in 
non-small cell T4 tumours with invasion of the mediastinum, 
recurrent nerve, heart, great vessels, trachea, oesophagus, 
vertebral body, and carina, or with malignant pleural effusion. 
 
Methods 
From 1977 through 1993, 89 patients underwent resection for 
primary non-small cell T4 carcinomas. Resection was regarded as 
complete in 34 patients (38.2%) and incomplete in 55 patients 
(61.8%). Actuarial survival time was calculated and risk factors for 
late death were identified. 
 
Results 
Overall hospital mortality was 19.1% (n=17). Mean 5-year 
survival was 23.6% for all hospital survivors, 46.2% for patients 
with complete resection and 10.9% for patients with incomplete 
resection (p=0.0009). In patients with complete resection, mean 
5-year survival for patients with invasion of great vessels was 
35.7%, whereas mean 5-year survival for invasion of other 
structures was 58.3% (p=0.05). Age, mediastinal lymph node 
involvement, type of operative procedure, and postoperative 
radiotherapy did not significantly influence survival. 
 
Conclusion 
In certain T4 tumours complete resection is possible, resulting in 
good mean 5-year survival especially for tumours with invasion of 
the trachea or carina. High hospital mortality makes careful 
patient selection imperative. 
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Introduction 
Prognosis in carcinoma of the lung is influenced by the stage of the disease and 
consequently by the therapeutic potential. Surgical resection is the treatment of 
choice for stage I and stage II non-small cell lung cancer, but its role in stage III 
disease remains unclear.1 Our previous studies have shown that complete 
resection will result in good survival in T3 bronchogenic carcinoma with chest 
wall involvement2, and in lung tumours invading mediastinal structures, or the 
main bronchus.3 These tumours are classified as stage IIB, or IIIA disease.4 Stage 
IIIB non-small cell lung cancer can be divided into primary bronchogenic 
carcinoma invading adjacent structures (T4), or into tumours with metastases to 
contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, 
or supraclavicular lymph node(s) (N3). T4 bronchogenic carcinomas are a 
heterogeneous group of locally advanced cancers. Generally, these T4 tumours 
are regarded as unresectable.5 Treatment is palliative for the majority of the 
patients, ranging from supportive care to chemotherapy or radiotherapy. 
However, some studies about extended resection of T4 tumours have been 
published6-10; hospital morbidity and mortality are high but, in selected patients, 
surgery appears to be beneficial and radical resection of the tumour has a 
potential for cure in the absence of mediastinal lymph node metastases.  
The present report is a retrospective analysis of survival characteristics in 89 
patients who underwent resection for T4 tumours with invasion of the 
mediastinum, recurrent nerve, heart, great vessels, trachea, oesophagus, 
vertebral body and carina or with a malignant pleural effusion. 
Materials and methods 
From 1977 through 1993, 2009 patients with bronchogenic carcinoma had a 
resection at our hospital. Of this group, 89 patients (4.4%) underwent operation 
for T4 non-small cell lung cancer (NSCLC) with invasion of the mediastinum, 
recurrent nerve, heart, great vessels (aorta, superior vena cava, proximal main 
pulmonary vessels (proximal defined as proxim to the pericard or at pericardial 
reflection)), trachea, oesophagus, vertebral body, or carina, or with malignant 
pleural effusion at pathologic examination. Patients with distant metastases, 
synchronous tumours, superior sulcus tumours, a satellite tumour within the 
same lobe or recurrences were excluded. Resection was considered complete 
when (1) the surgeon was morally certain that all known disease was removed, 
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(2) resection margins were histologically free, and (3) the highest mediastinal 
lymph node was negative by microscopy. Staging procedures included routine 
blood tests, thoracic computed tomography, ultrasonography of the upper 
abdomen, bronchoscopy, mediastinoscopy, and pulmonary function tests. 
Computed tomography of the brain or bone scintigraphy was performed only in 
case of clinical suspicion of metastatic disease. 
Patient characteristics are shown in Table 5.1. Cervical mediastinoscopy was 
negative in 81 patients (91.0%), not performed in 1 patient (1.1%) and positive 
in 7 patients (7.9%). These seven patients were operated because they only had 
one single positive lymph node at the ipsilateral tracheobronchial angle (n=4), 
or, because they were relatively young (46 and 51 years). In one patient the 
reason for thoracotomy could not be assessed retrospectively. One patient was 
pre-operatively diagnosed at bronchoscopy as having a carcinosarcoma in the 
main right bronchus. No cervical mediastinoscopy was performed. Frozen 
sections peroperatively showed a squamous cell carcinoma.  
 
Table 5.1. Patient characteristics 
 No. of patients 
Age (years)  
    Mean 61.5 
    Range 34-78 
Sex  
    Male  81 
    Female  8 
Smokers  82 
Symptoms*  
    Cough  65 
    Dyspnoea  37 
    Haemoptysis  35 
    Pain  34 
    Weight loss  24 
    No symptoms  10 
Side of tumour   
    Right  43 
    Left  46 
Preoperative diagnosis   
    Bronchoscopy  79 
    Percutaneous needle aspiration  3 
    No diagnosis  7 
* a patient presented with one or more symptoms 
 
The type of resection is shown in Table 5.2. In 4 patients with bronchogenic 
carcinoma invading the right side of the mediastinum, a pneumonectomy (n=3) 
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or lobectomy (n=1) included resection and reconstruction of the superior vena 
cava by a Goretex graft. Two patients had a lobectomy of the right upper lobe 
and a bypass of the superior vena cava. One patient had a lobectomy of the left 
upper lobe followed by a Dacron prothesis of the subclavian artery. In one 
patient with a pneumonectomy the tumour invaded the chest wall and an en 
bloc resection of the tumour and the chest wall was performed. 
 
Table 5.2. Operative procedures  
Procedure All patients 
(n=89) 
Patients with 
complete resection 
(n=34) 
Hospital survivors with 
complete resection 
(n=26) 
Pneumonectomy  56  19  14 
Sleeve pneumonectomy  4  3  3 
Carinal pneumonectomy  7  5  4 
En bloc pneumonectomy  1  1  0 
Pneumonectomy + reconstruction 
blood vessel 
 3  2  2 
Bilobectomy  1  0  0 
Lobectomy  6  2  1 
Sleeve lobectomy  5  2  2 
Lobectomy + reconstruction/ 
bypass blood vessel 
 4  0  0 
Sleeve bronchus  2  0  0 
 
A complete resection was achieved in 34 patients (38.2%). Resections were 
incomplete due to positive resection margins (n=39), positive lymph nodes 
(n=2), a combination of both (n=12) or malignant pleural effusion (n=2). The 
histological diagnosis was squamous cell carcinoma in 77 patients (86.5%), 
adenocarcinoma in 10 patients (11.2%), adenosquamous cell carcinoma in 1 
patient (1.1%), and large cell carcinoma in 1 patient (1.1%). Cervical 
mediastinoscopy was false negative in 27 patients. Fourteen of these 27 patients 
had positive subaortic or para-aortic lymph nodes (n=11) or positive 
paraesophageal lymph nodes (n=3). 
All patients were staged as T4 because of involvement of the mediastinum, 
recurrent nerve, heart, great vessels, trachea, oesophagus, vertebral body, or 
carina, or the presence of malignant pleural effusion (Table 5.3). Invasion of the 
different great vessels and pTNM staging are shown in Table 5.4 and 5.5. 
Radiation therapy was given to 47 patients as adjuvant therapy. One patient 
with tumour invasion of the pulmonary artery was pre-operatively irradiated. 
Although he was judged to be inoperable, a palliative pneumonectomy was 
carried out some months later because of persistent complaints of dyspnoea and 
the absence of distant metastases. Forty-six patients (51.7%) received 
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radiotherapy postoperatively. Of these patients, 32 patients had an incomplete 
resection. In the group of patients with complete resection (n=14), 7 patients 
were irradiated because they were staged as T4N2, the other 7 patients received 
radiotherapy because of the bulk of the tumour or localization near great vessels 
or other major structures. One patient with a T4N2 tumour only received 1.2 Gy 
radiation because she developed a pericardial effusion. Ten years after the 
operation she is still alive. 
Four patients (4.5%) received postoperative chemotherapy because of 
incomplete resection. 
 
Table 5.3. Structures involved in T4 tumours* 
Structure All patients 
(n=89) 
Patients with 
complete resection 
(n=34) 
Hospital survivors with 
complete resection 
(n=26) 
Great vessels  61  23  17 
Mediastinum  32  6  4 
Trachea  24  9  8 
Heart  15  4  4 
Recurrent nerve  13  8  6 
Oesophagus  12  3  3 
Carina  11  4  4 
Vertebral body  2  0  0 
Pleuritis carcinomatosa  2  0  0 
* = Involvement of more structures at the same time was possible 
 
Table 5.4. Invasion of the different great vessels 
Structure All patients 
(n=61) 
Patients with 
complete resection 
(n=23) 
Hospital survivors with 
complete resection 
(n=17) 
Aorta 17 6 3 
Superior vena cava 13 4 3 
Pulmonary artery   6 4 4 
Pulmonary vein 25 9 7 
 
Follow-up was completed as of August 2002. Follow-up data were obtained 
from hospital files and from questionnaires to referring pulmonary physicians 
and general practitioners. Follow-up about local recurrence and distant 
metastases was obtained in 96.6% of the patients. 
Survival was estimated from the date of operation, using the Kaplan-Meier 
survival analysis method.11 Hospital deaths were excluded. Survival comparisons 
were analysed by the log rank test.12 The difference was considered statistically 
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significant when the p value was less than 0.05. Incremental risk factors 
affecting survival were evaluated using Cox's proportional hazards model.13 
 
Table 5.5. pTNM staging  
pTNM All patients 
(n=89) 
Patients with 
complete resection 
(n=34) 
Hospital survivors with 
complete resection 
(n=26) 
pT4N0M0 11   4   3 
pT4N1M0 43 22 16 
pT4N2M0 35   8   7 
Results 
Hospital mortality was 19.1% (pneumonectomy 18.3% [13/71], lobectomy 
26.6% [4/15]. The mean age of these 17 patients was 64.4 years (51-77 years). 
Ten patients had undergone a pneumonectomy, 2 a carinal pneumonectomy, 1 
an en bloc pneumonectomy, 2 a lobectomy and 2 a lobectomy with 
reconstruction of the superior vena cava. Of these 17 deceased patients, 13 had 
invasion of the great vessels (4 left atrium and intrapericardial pulmonary vein, 
3 intrapericardial pulmonary vein, 3 aorta, 3 superior vena cava), 2 invasion of 
the trachea and oesophagus, 1 invasion of the trachea and 1 had tumour 
involvement of the vertebral column. Hospital deaths were due to cardiac arrest 
(n=5), sepsis (n=4), respiratory failure (n=3), haemoptysis (n=1), cerebral 
haemorrhage (n=1) and gastro-intestinal tract bleeding (n=1). Two patients 
died at home, 1 and 2 days respectively after their discharge from the hospital, 
but within 30 days of the operation.  
Estimated mean 5-year survival was 19.1% for all patients (n=89) and 23.6% 
for hospital survivors (n=72). 
Complete resection was performed in 26 hospital survivors (36.1%) with a mean 
5-year survival of 46.2%. The remaining 46 hospital survivors underwent an 
incomplete resection with a mean 5-year survival of 10.9 % (p=0.0009)(Figure 
5.1). Because of this significant difference in survival between patients with 
complete and incomplete resection, only the results of hospital survivors with 
complete resection were studied for the analysis of other prognostic factors. 
As for the N status, mean 5-year survival was 33.3% for 3 N0 patients, and 
43.8% and 57.1% for 16 N1 and 7 N2 patients, respectively (p>0.05).  
Regarding the T status, mean 5-year survival for patients with invasion of great 
vessels (n=14) was 35.7%, whereas mean 5-year survival for patients with 
invasion of other structures (n=12) was 58.3% (p=0.03) (Figure 5.2). Although 
patients with involvement of the carina or the trachea had a better mean 5-year 
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survival (50.9%) than involvement of other structures (44.4%), the difference was 
not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Estimated survival in hospital survivors with complete resection (——) and incomplete 
resection (- - -). + = censored cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Estimated survival after complete resection with invasion of great vessels (- - -) and 
invasion of other structures (——). + = censored cases. 
 
Of the 26 hospital survivors with complete resection, 24 patients had a 
squamous cell carcinoma with a mean 5-year survival of 45.8%. One patient 
with an adenocarcinoma died after 2 years and an other patient is still alive 
after 10 years.  
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Mean 5-year survival for patients who underwent a pneumonectomy (n=23) was 
43.5%, and for patients post lobectomy (n=3) 66.7% (p>0.05). Age and 
postoperative radiotherapy did not influence survival significantly. 
According to the multivariate analysis regarding age, sex, pTNM classification, 
histology and localization no significant prognostic factors were found in the 
group of patients with complete resection. 
Distant metastases developed in 4 of 26 hospital survivors with complete 
resection (15.4%), and 1 patient had a local recurrence (3.8%). Three patients 
had combined local and distant recurrence (11.5%). 
Discussion 
Prognosis, surgical treatment and long-term survival of non-small cell 
bronchogenic carcinoma are closely related to the stage of the disease.1 Stage 
IIIB non-small cell lung cancer has a 5-year survival rate of about 7%, and 
results of surgical treatment are poor4,6,14; however, some selected T4 tumours 
are potentially resectable, survival depending on completeness of resection, 
locoregional tumour invasion and lymph node metastases. These extended 
resections carry a high mortality and morbidity and make careful patient 
selection imperative. 
Hospital mortality varies between 5% and 20%, increasing after extended 
resections.15,16 Our study also shows a substantial hospital mortality of 19.1%. 
Hospital mortality was related to invasion of the great vessels. Thirteen of 17 
hospital deaths had tumour involvement of the aorta, superior vena cava or 
pulmonary veins. In this subset hospital mortality was 21.3% (13/61).  
Resectability of a tumour is influenced by pTNM staging. Our results of surgical 
treatment of T3 tumours with invasion of the chest wall, or with invasion of the 
mediastinal structures and/or localization in the main bronchus showed that 
complete resection was possible in 68.8% and 64.8%, respectively.2,3 
In T4 tumours, localization and invasion of adjacent structures often make 
complete resection impossible. A complete resection is vital.6,15 In our series, 
mean 5-year survival for complete resections was 46.2%, for incomplete 
resections 10.9% (p< 0.05).  
A complete resection could be performed in 34 patients (38.2%). This is higher 
than described by Martini et al. who had a complete resection rate of 18%. In 
that study none of the tumours invading the aorta, trachea or spine were 
resected.6 However, other studies reported complete resection rates of 72% and 
80%, respectively, for tumours invading great vessels or the carina.10,17 Based on 
resectability criteria, Grunenwald divided stage IIIB tumours in two 
subcategories: potentially resectable (invasion of superior vena cava, carina, 
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lower trachea, left atrium) and definitively non-resectable (malignant pleural 
effusion, invasion of the oesophagus and vertebrae).18 Our study supports this 
classification. 
In the past, high postoperative morbidity and mortality and uncertain long-term 
survival have been associated with carinal surgery for bronchogenic 
carcinoma.19 Respiratory failure after noncardiogenic pulmonary oedema or 
infection in the remaining lung and anastomotic dehiscence with bronchial 
fistula were the major postoperative problems and the main cause of the high 
operative mortality, varying from 11% to 27% in large series.8 However, careful 
patient selection, much attention to surgical details and careful anaesthetic 
management can lower the levels of surgical deaths. Recently, a postoperative 
mortality of 6.6%-15% has been reported and pneumonectomy with tracheal 
sleeve resection is advocated by several surgeons with 5-year survival 
approaching 43%.7,16 In our study, complete resection of tumours with invasion 
of the trachea or carina was 37.5% and 36.4% respectively, while it was less for 
tumours with invasion of other structures and it had a favourable prognosis with 
a mean 5-year survival of 50.9%. 
Results of surgery for T4 tumours with invasion of the left atrium or great vessels 
are poor. Burt et al. reported no 5-year survivors in their series of 18 patients 
after resection for tumours extending into the vena cava superior14, while 
Tsuchiya et al. found only 2 of 101 patients alive after 5 years.9 However, recent 
advances in cardiovascular surgery offer possibilities for complete resection in 
cases of invasion of the great vessels, like aorta and superior vena cava.10,15 
Spaggiari et al. reported extended resections for tumours invading the superior 
vena cava with 5-year actuarial survival of 29%, with 4 of 25 patients alive at 5 
years.10 Hospital mortality was 12%, and a complete resection was achieved in 
20 patients (i.e. 80%). This is high, but Doddoli et al. described the same results 
for completeness of resection and survival.17 In our study 37.7% of the patients 
with invasion of the great vessels had a complete resection (n=14). This 
conforms to the results of Fukuse et al.15 There was no difference in 
completeness of resection between invasion of the aorta, superior vena cava 
and pulmonary vein. The results of complete resection in the group with invasion 
of the pulmonary artery were better, but this was a very small group. Mean 5-
year survival was 35.7%.  
Traditionally, tumours invading vertebrae were considered as unresectable. We 
had no complete resection in both patients with involvement of the vertebral 
body. However, recent progress in spinal surgery has opened new possibilities. 
Induction treatment with total or partial vertebrectomy and pulmonary resection 
is feasible in selected patients with an estimated 5-year survival of 14%.20 
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In most studies involvement of the oesophagus precludes a complete 
resection.6,21 We achieved a complete resection in 3 patients (25%), as only the 
muscular layer of the oesophagus was involved by the tumour. 
Regarding lymph node involvement, mean 5-year survival was worse for N0 
patients than for N1 and N2 patients. This finding is contradictory to our 
previous studies2,3 in which mediastinal lymph node involvement worsens the 
prognosis. All 3 N0 patients in this series, however, had involvement of great 
vessels or the heart. Invasion of these structures carries a worse prognosis.6 In 
the group of 16 N1 and 7 N2 patients involvement of great vessels or the heart 
was present in 9 and 5 patients, respectively. The remaining patients had 
involvement of the trachea (n=8), carina (n=4), mediastinum (n=4) or 
oesophagus (n=3). Izbicki et al. also found no statistical significant differences 
in survival related to lymph node status in T4 tumours.22 In their study, mean 3-
year survival for 6 T4N0, 7 T4N1 and 12 T4N2 patients was 0%, 53% and 
16.6%, respectively. This suggests that in T4 tumours local invasion of 
surrounding structures may be more important for survival than lymph node 
involvement. But in both studies the number of patients is limited and other 
studies reported no long-term survivors in patients with T4N2 tumours.6,15,21 
Because of the poor results of surgical resection alone, multimodality treatment 
has surfaced as the treatment of choice in patients with stage III NSCLC.23 
However, it is still unclear which treatment modality (surgery, radiotherapy or a 
combination of both) will result in prolonged survival after neo-adjuvant 
chemotherapy. Recently, several trials have been conducted showing that some 
locally advanced, initially unresectable tumours become operable after 
inductionchemotherapy.24,25 
Given our own results, and those reported by others18,19,22 for patients presenting 
with T4 pathology, pre-operative work-up should establish the possibilities of 
complete resection using complete available modern imaging technology. If 
complete resection, with appropriate reconstruction, is feasible, all patients, 
otherwise fit for surgery, should be operated on. Complete resection resulting in 
good mean 5-year survival is possible, especially for tumours invading the 
trachea or carina. Tumours with invasion of the oesophagus, vertebrae and with 
malignant pleural effusion appear to be unresectable in most cases. The results 
of inductionchemotherapy make us propose that presently multimodality 
treatment offers new possibilities to treat patients with T4 disease and a good 
performance status. 
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Abstract 
Background 
The role of surgery after neo-adjuvant chemotherapy in patients 
with stage IIIB non-small cell lung cancer (NSCLC) remains 
unclear. 
 
Methods 
A prospective multicenter trial of neo-adjuvant chemotherapy 
followed by surgery or radiotherapy or both was conducted with 
41 patients with stage IIIB NSCLC. End points were toxicity, 
response, downstaging, complete resectability, and survival.  
The diagnostic value of repeat mediastinoscopy after neo-
adjuvant chemotherapy (three courses of gemcitabine/cisplatin) 
was also studied. 
 
Results 
Response rate after neo-adjuvant chemotherapy was 66% 
(27/41). Fifteen patients underwent repeat mediastinoscopy, 
which proved to be inadequate in 6 patients. Two repeat 
mediastinoscopies were false negative. Resection was 
performed in 18 patients, of which 10 proved to be radical. 
Hospital mortality was 2.4% (n=1). Major complications 
occurred in 6 patients (fistula, empyema, haemorrhage). 
Histopathologically proven downstaging was seen in 16 
patients (39%). Twenty-three patients underwent radiotherapy of 
whom 14 were diagnosed with stable/progressive disease and 
9 patients with partial/complete response. Median survival for 
all patients was 15.1 months, for non-responders 8.4 months 
and for responders 16.8 months (p=0.11). Patients with 
partial/complete response had a mean survival of 21.5 months 
after resection and 13.0 months after radiotherapy 
(p=0.0003). 
 
Conclusion 
Radical surgery can be performed in 37% (10/27) of the 
responders resulting in a prolonged survival. Surgery as part of 
combined modality treatment is feasible in stage IIIB NSCLC. 
Results of a repeat mediastinoscopy are disappointing and 
proved to be a not so effective restaging tool because of the 
high number of incomplete procedures and because it yields 
false negative results. 
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Introduction 
At presentation, 25 to 35% of all patients with non-small cell lung cancer 
(NSCLC) have tumours that have not yet metastasised systemically, but are 
locally too advanced to allow complete resection. Even though it could not cure 
the majority of patients, radiotherapy used to be the standard treatment in 
locally unresectable tumours.1 
Recently, multimodality treatment has become the standard therapy used for 
these patients.2 In combined modality treatment, the main goal of chemotherapy 
is to eradicate micrometastases and mediastinal lymph node metastases, and to 
diminish the size of the primary tumour. 
So far, most clinical trials of neo-adjuvant chemotherapy followed by surgery or 
radiotherapy or both have focused on patients with stage IIIA N2 disease.3 In 
this group, neo-adjuvant chemotherapy did achieve improved survival. However, 
the role of surgery after neo-adjuvant chemotherapy in patients with stage IIIB 
disease remains unclear. 
In this prospective phase II multicenter trial we evaluated the role of surgery after 
neo-adjuvant chemotherapy in patients with stage IIIB NSCLC. The diagnostic 
value of repeat mediastinoscopy after neo-adjuvant chemotherapy for 
mediastinal staging was also analysed. 
Methods 
Patients 
All patients with stage IIIB NSCLC were eligible: patients were staged as IIIB 
because of contralateral mediastinal lymph node metastases, or invasion of the 
mediastinum, heart, great vessels, trachea, oesophagus, vertebral body or 
carina. N3 nodes, or T4 primary lesions were confirmed either by means of 
cervical mediastinoscopy, thoracotomy or by anterior mediastinotomy. Further 
eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 or 1; platelet count 100 x 109/L; leukocyte count 3 x 
109/L; normal liver and renal functions; uni- or bidimensionally measurable 
disease; no active infections; no pregnancy or lactation; no other malignancies 
except carcinoma in situ of the cervix or basal cell carcinoma of the skin and no 
malignant pleural effusion or positive supraclavicular lymph nodes. Staging 
procedures included routine blood tests, thoracic computed tomography (CT), 
ultrasonography of the upper abdomen, bronchoscopy, mediastinoscopy, and 
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pulmonary function tests. Computed tomography of the brain and bone 
scintigraphy was performed only in case of clinical suspicion of metastatic 
disease.  
The study has been approved by the ethics committee in all participating centres. 
All patients were entered after written consent had been obtained. Multimodality 
treatment consisted of neo-adjuvant chemotherapy, which was followed by 
surgery or radiotherapy or both. 
Chemotherapy 
Neo-adjuvant chemotherapy consisted of three cycles of gemcitabine and 
cisplatin. Gemcitabine was administered on a weekly basis on days 1, 8 and 15 
at a dose of 1000 mg/m 2 (intravenously over 30 minutes) for 3 weeks followed 
by a 1-week rest throughout 28-day cycles. Cisplatin 100mg/m 2 (intravenously 
over 4 hours) was administered on day 2 of each 28-day course. Dose 
escalations were not allowed during this study. Treatment was stopped in those 
cases in which the disease progressed or unacceptable toxicity occurred. A 
complete blood cell count and differential cell count, serum electrolytes, renal 
and liver function were measured on day 1, 8, and 15 of each cycle. Doses for 
both gemcitabine and cisplatin were reduced to 75% if the leukocyte count was 
2.0 to 2.9 x 109/L and/or platelet count was 50 to 99 x 109/L. Chemotherapy 
was not given when the leukocyte count was less than 2.0 x 109/L, or the platelet 
count less than 50 x 109/L. The cisplatin dose was reduced to 50% if patients 
showed peripheral neurotoxicity grade 2. Cisplatin was omitted in case of 
peripheral neurotoxicity grade 3-4. The dose of cisplatin was reduced to 50% 
when the creatinine clearance was 40-60 ml/min. Cisplatin was not given in 
patients with a creatinine clearance less than 40 ml/min.  
Tumour assessment 
Response to neo-adjuvant chemotherapy was assessed after three cycles of 
chemotherapy. Restaging procedures included routine blood tests and thoracic 
CT. Other investigations were performed on indication. 
Complete response, throughout this study, was defined as the complete 
disappearance of all evidence of malignant disease as assessed by CT. Partial 
response was defined as at least 50% reduction in the product of the two largest 
perpendicular diameters in bidimensional measurable disease, or at least a 30% 
reduction of the largest diameter in unidimensional disease. Progressive disease 
was defined as at least a 25% increase of the product of the two largest 
perpendicular diameters in bidimensional measurable disease, or the largest 
diameter in unidimensional disease, or appearance of any new lesion not 
previously identified. All other patients were considered to have stable disease.  
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Surgery/radiotherapy 
Repeat mediastinoscopy was performed if mediastinal lymph node metastases 
were present at diagnosis in patients with complete, or partial response. Biopsies 
were taken at five different levels  (Naruke numbers: 2 right and left, 4 right and 
left, and 7). In case repeat mediastinoscopy showed no mediastinal lymph node 
metastases, surgical exploration was performed within 4 to 5 weeks after 
finishing chemotherapy. A pneumonectomy was performed in cases in which the 
tumour was located in the lower or middle lobe. In case the tumour was located 
in the upper lobe, a lobectomy was performed. Postoperative radiotherapy was 
given at a dose of 5640 cGy when resection margins were not free at 
histopathology, the tumour was not resectable, or ipsilateral mediastinal lymph 
nodes were found to be positive.   
When repeat  mediastinoscopy showed mediastinal lymph node metastases, 
patients were treated with radiotherapy alone at a dose of 5640 cGy with daily 
fractions of 235 cGy if only ipsilateral nodes were positive, and at a dose of 
3900 cGy in 13 fractions if contralateral nodes were involved. Follow-up visits 
were made every 3 months. 
Statistics 
Survival was estimated from the date of inclusion, using the Kaplan-Meier 
survival analysis method.4 Survival comparisons were analysed by means of the 
log rank test.5 The difference was considered statistically significant when the p 
value was less than 0.05. 
The follow-up was complete as of February 1, 2002. Follow-up data were 
obtained from hospital files and from questionnaires to referring pulmonary 
physicians and general practitioners.  
Results 
From January 1997 until September 1999, 41 patients with stage IIIB NSCLC 
were entered into this trial. Ages ranged from 39 to 73.6 years with a mean of 
60.5 years. Thirty-one patients were male. Twenty-six tumours were located on 
the right side. Cervical mediastinoscopy proved to be positive in 29 patients 
(70.7%). In this group, eight patients showed positive N2 nodes and 21 positive 
N3 nodes. Clinical TNM classification is shown in Table 6.1. The histological 
diagnosis was adenocarcinoma in 17 patients (41.5%), squamous cell 
carcinoma in 15 patients (36.6%), and large cell carcinoma in 9 patients 
(21.9%). 
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Table 6.1. Clinical TNM classification 
cTNM All patients 
(n=41) 
cT2N3 12 
cT3N3   4 
cT4N0 12 
cT4N2   8 
cT4N3   5 
Induction chemotherapy and response 
Thirty-seven patients (90%) received three cycles of gemcitabine and cisplatin. 
Four patients did not continue treatment after two cycles of chemotherapy 
because they developed either asthenia (n=3) or microangiopathy with 
progressive disease (n=1). In all 4 cases early evaluation took place. The 
patients were further treated with radiotherapy. 
The radiological response to neo-adjuvant chemotherapy is presented in Table 
6.2. The response rate after neo-adjuvant chemotherapy was 66% (27/41). Two 
patients showed a complete response. 
 
Table 6.2.  Response after induction chemotherapy 
Response All patients 
(n=41) 
Complete response   2 
Partial response 25 
Stable disease   7 
Progressive disease   7 
Surgical treatment and radiotherapy 
Repeat mediastinoscopy was performed on 15 patients without complications. 
The results are shown in Table 6.3.  
 
Table 6.3.  Results of repeat mediastinoscopy (n=15) 
 T4N0 T4N2 T1-3N3 T4N3 Total 
Repeat mediastinoscopy 0 2   6 1   9 
No repeat mediastinoscopy 8  2*   1 1 12 
Inadequate 0 2   3 1   6 
Total 8 6 10 3 27 
* At presentation mediastinal lymph node metastases in aortic pulmonary window (Naruke no. 5) 
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Either no biopsies or incomplete biopsies were obtained in 6 patients (40%), 
owing to fibrosis or adhesions or both. Of all patients with an adequate repeat 
mediastinoscopy (n=9), 2 had positive nodes. Seven biopsies showed negative 
results. In 2 patients (28.6%), this result proved to be false negative at 
thoracotomy. Surgical procedures are shown in Table 6.4. 
 
Table 6.4.  Results of surgery (n=20) 
Group No. of patients Types of Resection No. of patients 
Resection 18 Pneumonectomy 7 
  Sleeve pneumonectomy 1 
  Bilobectomy 1 
  Lobectomy 7 
  Lobectomy and chest wall resection 1 
  Sleeve lobectomy 1 
  Complete resection          10 
Unresectable   2   
 
Surgical pathology for each subset of clinically staged patients is shown in Table 
6.5. Histopathological downstaging was proven in 16 patients (39.0%). 
 
Table 6.5.  Histopathologically proven downstaging (n=16) 
cTNM No. of Patients RpTNM No. of patients 
cT2N3 6 RpT0N0 1 
  RpT0N1 1 
  RpT1N2 1 
  RpT2N0 1 
  RpT2N2 2 
cT3N3 3 RpT1N1 1 
  RpT3N0 2 
cT4N0 5 RpT0N0 1 
  RpT1N1 1 
  RpT2N0 2 
  RpT2N1 1 
cT4N2 1 RpT3N1 1 
cT4N3 1 RpT4N2 1 
 
Twenty-three patients (61%) received radiotherapy, 14 patients with stable, or 
progressive disease (3900 cGy) and 9 patients with partial response (3900 to 
5640 cGy). In the latter group, 3 patients underwent a positive repeat 
mediastinoscopy, 2 patients continued to have a T4 tumour at thoracotomy, and 
1 patient showed progression of the tumour before surgery. Resection was not 
possible owing to insufficient predicted postoperative pulmonary function in 2 
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patients. One patient showed a suspect lesion on bone-scintigraphy, although 
metastatic disease could not be proven histologically. This patient was treated 
with radiotherapy instead of surgery, as there was suspicion of bone metastases. 
Treatment of the responders in relation to clinical TNM classification is shown in 
Table 6.6. 
 
Table 6.6.  Treatment of responders in relation to cTNM 
Treatment cT2-3N3 cT4N0-2 cT4N3 Total 
Surgery   9   8 1 18 
Radiotherapy   1   6 2   9 
Total 10 14 3 27 
 
Treatment-related complications 
Hospital mortality was 2.4% (n=1). The patient had a complete, intrapericardial 
pneumonectomy without complications. Two days after discharge from the 
hospital this patient was admitted with septic shock due to purulent pericarditis 
and an empyema without fistula. The patient died 2 days later. Other 
complications occurred in 6 patients. Three had a bronchopleural fistula with 
empyema after pneumonectomy. In 2 patients the resection was incomplete 
because of residual tumour at the bronchial stump. Haemorrhage occurred in 3 
other patients, 2 of whom needed rethoracotomy. 
Survival 
After a median follow-up of 46 months, 36 patients had died. The estimated 
median survival for the whole group was 15.1 months [95% confidence interval 
[CI]=11.2 to 19.1] with an estimated 1-year, 2-year, and 3-year survival of 
60%, 25%, and 15%, respectively (Figure 6.1).  
Response was found in 27 patients with a median survival of 16.8 months [95% 
CI =12.7 to 20.8]. The remaining 14 patients had stable, or progressive disease 
with a median survival of 8.4 months [95% CI =6.9 to 10.0] (p=0.11) (Figure 
6.2). 
Patients with partial or complete response had a median survival of 21.5 months 
[95% CI =7.75 to 35.2] if resection was done, and 13.0 months [95% CI =7.7 
to 18.3] when treated with radiotherapy (p=0.0003) (Figure 6.3). Of the 10 
patients with a complete resection, 5 are still alive. One of these patients had 
radiotherapy because of local recurrence, the other 4 patients have no disease 
activity. Five patients died after complete resection: 1 of the complications of the 
operation, 2 with local recurrence and 2 with distant metastases.  
 Combined modality treatment in stage IIIB NSCLC  91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1  Estimated survival of all patients (n=41) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2  Estimated survival of patients with stable/progressive disease (n=14) (- - -) and patients 
with complete/partial response (n=27) (——).  
 
Patients with T4N0 disease (12/41) had a median survival of 15.1 months [95% 
CI =12.1 to 18.1] versus a median survival of N2/N3 disease (29/41) of 14.6 
months [95% CI =10.3 to 19.00] for the whole group. There is no significant 
difference in median survival between the T4N0 group and the N2/N3 group 
(p=0.46).  In the group of patients with partial or complete response (27/41), 
patients with T4N0 disease (8/41) had a median survival of 15.1 months [95% 
CI =12.7 to 17.6] versus a median survival of the N2/N3 group (19/41) of 
17.5 months [95% CI =13.3 to 21.8]. Again there is no significant difference 
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between the T4N0 group and the N2/N3 group in the group of patients with 
partial of complete response (p=0.99). 
Distant metastases developed in 8 of 27 patients with complete or partial 
response (29.6%). Brain metastases occurred in 6 (22.2%). Eight patients had 
local recurrence (29.6%). Two patients had combined local and distant 
recurrence (7.4%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Estimated survival in responders treated with surgery (n=18) (——) or radiotherapy 
(n=9) (- - -). 
Comment 
Surgery is the treatment of choice in patients with NSCLC but resectability is 
closely related to the stage of the disease.6 Whereas stage I and II tumours are 
considered to be resectable, the role of surgery for stage IIIB NSCLC remains 
controversial.7 In the series by Mountain 5-year survival is 7% for clinical T4 and 
3% for N3 disease.8 Death of patients with stage III NSCLC is more often caused 
by distant metastases rather than local disease, and patients are rarely cured 
with local treatment modalities alone. Therefore, multimodality treatment has 
surfaced as the treatment of choice in a selected group of patients with stage III 
NSCLC.2,9 However, it is still unclear which treatment modality (surgery or 
radiotherapy or both) will result in prolonged survival after neo-adjuvant 
chemotherapy.  
Over the years, the optimal chemotherapy has proved hard to define. Meta-
analyses has indicated that the chance of survival increases when a platinum-
based regimen is being used.9,11 Numerous combinations of cisplatin and older 
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drugs have been used with no single mix emerging as the superior combination. 
Although several single-agents have been producing response rates of 15 to 
20%, combination chemotherapy is still considered the standard of care.12 The 
combination of cisplatin and gemcitabine has shown significant activity in 
advanced non-small cell lung cancer with response rates as high as 70% in 
several phase II studies.13 
The optimal duration of induction chemotherapy remains controversial as well. 
The American Society of Clinical Oncology guidelines proposed a duration of 2 
to 8 cycles.2 Crino and associates14, who studied the gemcitabine/cisplatin 
regimen as induction chemotherapy in 42 patients with stage IIIA (n=11) and 
IIIB (n=31), achieved an overall response rate of 62%. Complete resection could 
be achieved in 10 patients, with tumour downstaging in 9. Similar results have 
been reported by Van Kooten and colleagues15 and Abratt and coworkers.16 
Our study showed a response rate of 66% after induction chemotherapy. Two 
patients responded completely. Albain and coworkers found in their research an 
even higher response rate, when using a trimodality approach of concurrent 
chemotherapy and irradiation followed by surgery in patients with stage IIIA and 
IIIB NSCLC. Resectability in their case was 80% for the entire IIIB group.17 
In the past, repeat mediastinoscopy has been considered to be contra-indicated, 
as it was perceived to be too hazardous to dissect the scarred mediastinum.18 
Between 1976 and 1990, 140 patients underwent repeat mediastinoscopy in 
our hospital as a routine staging procedure. No mortality occurred. Sensitivity 
was 74%, and accuracy 94%.19 
Mediastinal structures become differently affected after neo-adjuvant 
chemotherapy. The cytotoxic drugs change the normal inflammatory response 
and adhesions. Additionally nodal tissue can be seriously distorted. During our 
research, the 15 patients who underwent repeat mediastinoscopy, did not show 
complications, such as described by Pauwels and associates and Mateu-Navarro 
and colleagues.20,21 However, 40 % remained incomplete owing to fibrosis and 
adhesions. Beside that, 2 out of 7 proved to be false negative. Comparable 
figures were reported by Pauwels and coworkers (25%), and Mateu-Navarro and 
associates (40%).20,21 Hence, this paper argues that repeat mediastionoscopy 
after neo-adjuvant chemotherapy is a not the most effective restaging tool. The 
promising results of PET-scanning in staging NSCLC22,23 make it an attractive 
alternative for selecting patients with negative mediastinal lymph nodes after 
neo-adjuvant chemotherapy. A prospective pilot study of FDG-PET-scan after 
neo-adjuvant chemotherapy in stage IIIA NSCLC of Vansteenkiste showed an 
accuracy of 100%.22 
In this study a thoracotomy was performed on 20 patients. In 2 cases the tumour 
proved to be unresectable. Although 8 patients underwent a pneumonectomy, 
hospital mortality was low (2.4%). Complications occurred in 6 patients, 4 of 
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them underwent a pneumonectomy. Three patients suffered from a 
haemorrhage and 3 had a bronchopleural fistula with an empyema. A complete 
resection was performed in 10 responders (24.4%). Survival in this group was 
better than survival among patients with a stable or progressive disease. 
However, this difference was not significant. For all responders, survival proved 
significantly better among patients who underwent surgery than among patients 
treated with radiotherapy. 
The brain is a major site of distant metastases.17 In this study, 6 responders 
developed brain metastases (22.2%). Few studies have routinely used 
prophylactic cranial irradiation. Eberhardt and colleagues did not perform a 
randomised investigation of prophylactic cranial irradiation in their study, but 
the overall brain relapse was remarkably reduced in the group that received 
prophylactic cranial irradiation, even though no impact on survival was noted. 
Large prospective randomised studies are necessary to evaluate the role of 
prophylactic cranial irradiation.24 
In conclusion: these data show that radical surgery can be performed in 37% 
(10/27) of the responders and can result in prolonged survival. Surgery as part 
of combined modality treatment is feasible for patients with stage IIIB NSCLC. 
Results of repeat mediastinoscopy are disappointing and proved to be a not so 
effective restaging tool because of the high number of incomplete procedures 
and because it yields false negative results. 
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Summary 
Surgery is the treatment of choice for patients with stage I and II non-small cell 
lung cancer (NSCLC). However, the role of surgery in the treatment of stage III 
NSCLC remains unclear. The aim of this thesis was to evaluate results of 
resection of different subtypes of T3 and T4 NSCLC and to analyse the 
characteristics and prognosis of each subgroup. Also, results of surgery in 
patients with stage IIIB NSCLC treated with induction chemotherapy, and the 
role of repeat-mediastinoscopy were discussed.  
Chapter 1 
The introduction provides an overview of general aspects of NSCLC, like 
epidemiology, carcinogenesis, histology, clinical features, and diagnosis. 
Accurate staging is important as it determines treatment pathways. For stage I 
and II NSCLC surgical treatment is evidence based, whereas for stage III disease 
there is no “standard” therapy. Treatment may include combinations of 
induction chemotherapy, radiotherapy and surgery. To patients with stage IV 
NSCLC surgery only offers trauma, and thus, they should be treated with either 
palliative chemotherapy or best supportive care. Survival is closely related to the 
stage of the disease.  
The chapter focuses on patients with T3 and T4 NSCLC. T3 tumours comprise a 
heterogeneous group, including tumours with invasion of the chest wall, 
mediastinal structures, or diaphragm, Pancoast tumours, tumours with 
involvement of the main bronchus within 2 cm of the carina, and tumours 
associated with atelectasis or obstructive pneumonitis of the entire lung. These 
tumours are suitable for surgical treatment if no metastases are present. 
Prognosis depends on the completeness of the resection and the presence of 
lymph node metastases. Characterisation of the primary tumour as T4 includes 
invasion of the mediastinum, heart, great vessels, trachea, oesophagus, 
vertebrae, carina, or the presence of malignant pleural or pericardial effusion, 
or satellite tumour nodule(s) within the same lobe as the primary tumour. Thus, 
T4 tumours also encompass heterogeneous subgroups, invading other vital 
structures. Surgical treatment is limited to highly selected patients. 
Chapter 2 
This chapter is an analysis of the results of en bloc resection or extrapleural 
dissection in 125 patients with chest wall involvement. An important factor in the 
 100  Chapter 7 
treatment of lung cancer with chest wall invasion is the question whether an 
extrapleural dissection, or en bloc resection has to be performed in patients with a 
tumour adjacent to the parietal pleura. In this series, no difference was found in 
mean 5-year survival between both operative procedures when only the parietal 
pleura was involved. When the surgeon could finger-dissect the parietal pleura 
from the ribs, such an extrapleural dissection was carried out (n=73). When 
adherence of the tumour to the thoracic wall precluded digital dissection, an en 
bloc resection was performed (n=52). A complete resection was achieved in 86 
patients (68.8%). Hospital mortality was 3.2%, with no significant difference 
between en bloc resection and extrapleural resection. In most patients, resection 
consisted of a lobectomy (n=86) and the number of resected ribs ranged from one 
to four. Mean 5-year survival was 24% for all hospital survivors, 29% for hospital 
survivors with complete resection and 11% for hospital survivors with an incomplete 
resection (p<0.001). The difference in mean 5-year survival for hospital survivors 
between N0 and N2 tumours was statistically significant (36% and 14%, 
respectively). The tumour was opened peroperatively in 7 patients, all of whom 
died within 16 months. It was concluded that both operative procedures yield good 
survival results. Incompleteness of resection, intrapleural tumour spill, and N2 
involvement influenced survival adversely. No relation was found between survival 
and age, depth of chest wall invasion and postoperative radiotherapy in patients 
with complete resection. 
Chapter 3  
This chapter evaluates the retrospective results of resection of 108 patients with 
centrally located T3 tumours. Patients were divided into 3 subgroups. The first 
group included 33 patients with a T3 tumour due to invasion of mediastinal 
structures, like mediastinal pleura, phrenic nerve, or pericardium. In the second 
group (n=68), tumours were staged as T3 because they were located in the main 
bronchus less than 2 cm of the carina. The last group included patients with a 
combination of both tumours (n=7). A complete resection was performed in 70 
patients (64.8%). In the subgroups analysed in this study, most tumours were 
squamous cell carcinomas (83.3%) and resection mostly consisted of a 
pneumonectomy (82%). Only a few patients had a sleeve lobectomy. Overall 
hospital mortality was 8.3% (n=9), 10% for pneumonectomy and 0% for 
lobectomy. Most of the hospital deaths were due to bronchopleural fistula. Mean 5- 
year survival was 29% for all hospital survivors, 35% for hospital survivors with 
complete resection, and 18% for hospital survivors with incomplete resection 
(p=0.03). Regarding T3 subgroups, tumours located in the main bronchus had a 
more favourable prognosis with a mean 5-year survival of 40%, but the difference 
between this subgroup and hospital survivors with T3 tumours due to mediastinal 
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involvement (mean 5-year survival 25%) was not statistically significant. 
Incompleteness of resection and mediastinal lymph node involvement were 
significant adverse prognostic factors. No patient with N2 disease survived more 
than 5 years. 
Chapter 4 
This chapter is a review of the clinical characteristics, diagnosis, tumour staging, 
treatment and survival of superior sulcus, or, Pancoast tumours. Due to their 
location in the apex of the lung and invasion of surrounding structures (brachial 
plexus, first ribs, stellate ganglion, subclavian vessels, or vertebrae) these 
tumours cause specific symptoms, like pain in the arm or shoulder or Horner’s 
syndrome. Pancoast tumours can be staged as a T3 or T4 tumour, depending 
on invasion of adjacent structures. Survival is better for the first group. 
Incompleteness of the resection, mediastinal lymph node involvement and 
Horner’s syndrome have been found to be a negative prognostic factor. The 
classic treatment for these tumours, introduced by Shaw and Paulson, has been 
preoperative radiotherapy followed by surgery, with a mean 5-year survival of 
approximately 30%. Surgery usually consists of en bloc resection of the involved 
ribs with a lobectomy. Common surgical techniques used to approach the 
tumour are the classic posterior Shaw-Paulson approach or the newer anterior 
transcervical technique introduced by Dartevelle. 
Recent results of combination of chemoradiotherapy and surgical resection 
suggest that this combined modality treatment offers the best survival results for 
Pancoast tumours, but careful patient selection and adequate peri-operative 
monitoring are essential, regarding the higher rates of mortality and morbidity 
after neo-adjuvant therapy. 
Chapter 5 
T4 tumours encompass heterogeneous subgroups and the role of extended 
resections for these tumours invading vital structures remains doubtful. However, 
good survival results after extended resection have been described in selected 
patients. In this chapter results of 89 patients who underwent resection for primary 
non-small cell T4 carcinomas were analysed. It was shown that a complete 
resection was possible in 38.2% of the patients (n=34). Mean five-year survival 
was 46.2% for hospital survivors with complete resection and 10.9% for hospital 
survivors with an incomplete resection (p<0.05). Most complete resections were 
achieved in patients with invasion of the carina, trachea, or great vessels. 
Surgery mostly consisted of pneumonectomy (n=71). Hospital mortality was 
high (19.1%), which highlights the importance of careful patient selection. Best 
survival results were described for patients with tumours located in the trachea or 
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carina, with a mean 5-year survival of 50.9%. Patients with invasion of the great 
vessels had a lower survival rate of 35.7%. In this study no relation was found 
between mediastinal lymph node metastases and survival, but the number of 
patients was limited. Also age, operative procedure, and postoperative 
radiotherapy did not significantly influence survival. 
Chapter 6 
Recently, multimodality treatment has become the recommended therapy for 
patients with locally advanced tumours. In this chapter, results of a prospective 
multicentre trial of neoadjuvant chemotherapy followed by surgery or 
radiotherapy or both in 41 patients with stage IIIB non-small cell lung cancer 
were evaluated. Response to neoadjuvant chemotherapy was shown in 27 
patients (66%). It was reported that radical surgery with acceptable hospital 
mortality could be performed in 37% of the responders (n=10) and that survival 
was better for these patients than for responders treated with radiotherapy (21.5 
versus 13.0 months). Major complications occurred in 6 patients (fistula, 
empyema, haemorrhage). Histopathological downstaging was proven in 16 
patients (39%). The diagnostic value of repeat mediastinoscopy after 
neoadjuvant chemotherapy for mediastinal staging was also analysed. Fifteen 
patients underwent repeat mediastinoscopy which proved to be inadequate in 6 
patients and false-negative in 2.  
It was concluded that surgery as part of combined modality treatment is feasible 
in stage IIIB NSCLC. Results of repeat mediastinoscopy are disappointing due to 
the number of incomplete procedures, caused by fibrosis and adhesions, and 
because it yields false negative results. 
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Concluding remarks 
The data presented in this thesis confirm that surgery is the treatment of choice 
for patients with a T3 tumour. The most important goal of surgical therapy is a 
complete resection, as an incomplete resection predicts poor survival. Regarding 
the several subgroups of T3 tumours in our studies, a complete resection was 
achieved in 68.8% of tumours with chest wall invasion, and in 64.8% of centrally 
located T3 tumours. Review of the literature reveals that most of the articles 
studying T3 NSCLC concern tumours with chest wall invasion or superior sulcus 
tumours. Only a few reports have also focused on other subgroups, like tumours 
with mediastinal involvement and tumours located in the main bronchus less 
than 2 cm of the carina. Results of these limited data suggest that patients with 
chest wall invasion are a favourable subgroup. This is explained by a higher 
chance to achieve a complete resection. To ensure complete resection, surgery 
of T3 tumours usually consists of en bloc resection of the tumour and involved 
structures. In patients with centrally located tumours and superior sulcus tumours 
resections with wide margins are more difficult to perform due to the presence of 
vital structures in the mediastinum or the apex of the lung.  
In tumours invading the parietal pleura or chest wall the choice of operation (en 
bloc resection of the tumour and chest wall or extrapleural resection) is based on 
pre- and intraoperative assessment. Peroperatively, pathological examination of 
resection margins is recommended to assess completeness of resection. In case 
of doubt, an en bloc resection should be performed, as incomplete resections, 
even if only microscopic disease, and intrapleural tumour spill offer the patient 
no curative benefit. Patients with tumours located in the main bronchus within 2 
cm of the carina are generally treated with a pneumonectomy or sleeve 
lobectomy. As hospital mortality increases in a pneumonectomy, a sleeve 
lobectomy should be considered as an alternative treatment in more patients. 
Another important factor regarding survival of resected T3 tumours is the 
presence of mediastinal lymph node metastases. It is generally known that nodal 
disease confers a poor prognosis and that survival decreases with increasing 
nodal stage. Our studies showed that in all three T3 subgroups, N2 disease is 
highly unfavourable. Similar results have been published for Pancoast tumours. 
Therefore, distinction between N0-1 and N2 disease is essential, as patients with 
mediastinal lymph node metastases are no candidates for primary resection, but 
for treatment with induction chemotherapy. This stresses the importance of 
appropriate staging of the tumour preoperatively by radiological investigation 
(CT / PET scanning) and histological assessment of mediastinal lymph nodes by 
mediastinoscopy.  
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In our studies, mean 5-year survival for several subgroups of patients with 
resected T3 NSCLC varies between 24 % and 40%. Superior survival was 
reported for patients with tumours located in the main bronchus, although the 
difference was not significant. Some authors published similar results, whereas 
others demonstrated a survival benefit for tumours with chest wall invasion. 
However, it is difficult to compare these studies because patient selection and the 
method of reporting are not consistent. Large comparative studies between 
several T3 subgroups are needed to answer the question if there is a subgroup 
with a favourable prognosis. 
In recent years, several trials have been conducted to examine the role of 
induction chemotherapy or chemoradiotherapy in patients with stage IIIA and 
stage IIIB disease. Results of these studies are encouraging by showing high 
response rates and an increase in the number of complete resections. For that 
reason it seemed logical to apply this combined treatment to patients with 
Pancoast tumours. The available data suggest that in these patients a tri-
modality approach, involving induction chemoradiotherapy followed by surgical 
resection, achieves the best survival. The usefulness of this approach in other T3 
tumours will need further investigation and patients should be enrolled in trials 
to investigate if survival improves by combined modality treatment. Until now, 
adjuvant therapy (radiotherapy or chemotherapy) has not shown survival benefit 
in patients with complete resection. 
The historical difference between T3 and T4 tumours is the determination of 
resectability. Generally, stage IIIB NSCLC is defined as an unresectable disease. 
However, T4N0-1 disease has been shown to be biologically different from N3 
disease, and although surgery for T4 tumours remains a difficult question, some 
patients with a T4 tumour can indeed be candidates for resection. Although 
several reports have demonstrated the technical feasibility of resection of T4 
structures, few data are published about long-term survival. The largest 
experience and the best results for long-term survival are described in patients 
with T4 tumours invading the carina and trachea. Even though recent progress 
in cardiovascular and spinal surgery has opened new possibilities for patients 
with invasion of great vessels, heart or vertebrae, surgical treatment of these 
tumours mostly results in limited survival. Also invasion of the oesophagus 
mostly precludes a complete resection. Aggressive surgical resection in T4 
tumours has been associated with high hospital mortality rates of 15-20%. 
Regarding this increased mortality and the limited survival, it is important to 
accurately stage and select patients, and refer them to a centre with experience 
in performing extended resections.  
Several trials of combined modality treatment have demonstrated that this 
therapy should be the first choice for patients with T4 disease and good 
performance status. The aims of induction chemotherapy prior to resection or 
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radiotherapy are to improve local control by downstaging the primary tumour 
and nodal metastases and to eradicate systemic micrometastases. Many options 
are currently available with regard to the optimum chemotherapeutic regimen as 
induction chemotherapy. Platinum-based chemotherapy has become the most 
effective and widely used.  
It remains an important issue to demonstrate histopathological downstaging, as 
patients with persistent N2/N3 disease do not benefit from surgical resection. 
Repeat mediastinoscopy does not seem a useful tool for restaging of the 
mediastinum after induction therapy due to false negative results and incomplete 
procedures. This stresses the need to search for other restaging techniques. 
Positron emission tomography is a promising modality in lung cancer staging. 
However, only few data exist about the role of PET in restaging after induction 
chemotherapy. Its accuracy has not been determined in prospective trials and 
further studies are needed to define this issue. Recently, other techniques have 
been developed for evaluating mediastinal lymph nodes. It is expected that both 
transoesophageal and transbronchial endoscopic ultrasound guided fine needle 
aspiration will prove to be valuable for the restaging of mediastinal lymph 
nodes.  
Although surgical treatment can achieve effective local control, many patients 
who have previously undergone a complete resection of the primary tumour, 
develop distant metastases. As brain metastases are one of the most common 
forms of relapse, the question has been raised whether patients with a complete 
resection should be treated with prophylactic cranial irradiation (PCI) to improve 
the control of distant metastatic disease and survival. At this moment, limited 
data about the routine use of PCI in patients with NSCLC suggest that the overall 
brain relapse will reduce. 
Over the last decade, the use of new chemotherapeutic agents, used single or in 
combination, appears to have improved survival in patients with NSCLC. 
Recently, taking into consideration the comparable survival results of many 
phase III trials, progress seems to have reached a plateau. Progress in 
understanding the molecular biology of NSCLC has lead to the identification of 
new pharmacologic agents. These include angiogenesis inhibitors, tyrosine 
kinase inhibitors, which block signal transduction, and immunotherapy. These 
agents are currently being tested in phase I and II trials. Whether a combination 
of these agents with traditional therapeutic strategies, such as surgery, 
radiotherapy, and cytotoxic chemotherapy will result in better survival needs to 
be defined.  
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Samenvatting 
Jaarlijks wordt wereldwijd bij 1,2 miljoen mensen de diagnose longkanker 
gesteld en overlijden 1,1 miljoen mensen aan deze ziekte. Hiermee is 
longkanker de meest voorkomende vorm van kanker en een belangrijke 
doodsoorzaak. De incidentie is het hoogst in Noord-Amerika en Europa. De 
laatste jaren komt longkanker steeds meer bij vrouwen voor terwijl het aantal 
mannen met longkanker daalt. De belangrijkste verklaring voor deze tendens is 
een verandering in het rookgedrag. Er bestaat een direct verband bestaat tussen 
roken en het ontwikkelen van longkanker, daar door rook veroorzaakte prikkels 
kunnen leiden tot veranderingen in het genetische materiaal van een cel. 
Hierdoor treedt een ongeremde deling van cellen op, hetgeen leidt tot de 
vorming van een tumor. 
De meeste patiënten presenteren zich met klachten zoals hoesten, 
kortademigheid, bloed ophoesten, pijn en heesheid. Het probleem bij 
longkanker is dat deze klachten meestal pas in een laat stadium optreden 
waardoor een curatieve behandeling vaak niet meer mogelijk is. Als gevolg 
daarvan is de prognose ongunstig, met een gemiddelde 5-jaarsoverleving van 
15%.  
Als er verdenking bestaat op de aanwezigheid van een longtumor wordt verder 
onderzoek verricht. Voor het stellen van de diagnose longkanker is 
weefselonderzoek nodig. Dit weefsel wordt meestal verkregen door middel van 
een bronchoscopie of longpunctie. Aanvullende beeldvormende diagnostiek 
bestaat uit röntgenfoto’s, computertomografie (CT scan), magnetic resonance 
imaging (MRI scan), echografie en positron emission tomografie (PET scan). Een 
mediastinoscopie is bij veel patiënten noodzakelijk om mediastinale 
lymfkliermetastasen aan te tonen dan wel uit te sluiten. Het doel van 
bovenstaande onderzoeken is om de tumor adequaat te stadiëren aan de hand 
van de TNM-classificatie. Deze beschrijft de grootte en plaats van de tumor en 
de mate van ingroei in de omringende weefsels (T) en de aanwezigheid van 
metastasen in de mediastinale lymfklieren (N) en/of metastasen elders in het 
lichaam (M). 
Longkanker kan worden onderverdeeld in 2 hoofdgroepen: het kleincellige type 
en het niet-kleincellige type. Het kleincellige type longkanker is een zeer 
agressieve vorm van longkanker, die frequent metastasen vormt en die daarom 
meestal behandeld wordt met chemotherapie al dan niet in combinatie met 
radiotherapie. Bij ongeveer 80% van de patiënten is sprake van een niet-
kleincellige longtumor. De behandeling en prognose van dit type longtumor is 
sterk afhankelijk van het stadium van de ziekte op het moment van presentatie. 
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Dit stadium wordt bepaald door de TNM-classificatie. Voor patiënten met een 
stadium I en II tumor (longtumoren zonder lymfklieraantasting of met alleen 
metastasen in hilaire of intrapulmonale lymfklieren) is chirurgische resectie van 
de tumor met het omringende longweefsel de aangewezen behandeling, mits de 
cardiopulmonale reserves voldoende zijn. Voor patiënten met een stadium III 
tumor (aanwezigheid van metastasen in mediastinale lymfklieren of ingroei van 
de tumor in belangrijke omringende structuren) is er geen standaard therapie. 
Behandeling bestaat uit een combinatie van chemotherapie, chirurgie en 
radiotherapie. Patiënten met een stadium IV tumor (metastasen elders in het 
lichaam) komen in aanmerking voor palliatieve behandeling. Deze is gericht op 
het remmen van de ziekte en op vermindering van de klachten en bestaat uit 
chemotherapie of radiotherapie. Daarnaast bestaat de mogelijkheid te kiezen 
voor een afwachtend beleid.  
 
Dit proefschrift omvat een aantal studies waarin de resultaten van chirurgische 
behandeling van diverse subgroepen van T3 tumoren (stadium II/III) en T4 
tumoren (stadium III) worden besproken. Doel van het onderzoek was om 
verschillende subgroepen met elkaar te vergelijken en te bepalen welke factoren 
van belang zijn voor de prognose. In de studies is een resectie als compleet 
beschouwd als 1) de chirurg er macroscopisch zeker van was dat hij de gehele 
tumor verwijderd had, 2) de snijvlakken vrij waren van tumorweefsel bij 
pathologisch-anatomisch onderzoek en 3) de hoogste gebiopteerde 
mediastinale lymfklier negatief was.  
Daarnaast worden de resultaten gepresenteerd van chirurgische behandeling 
van patiënten met een stadium IIIB niet-kleincellige longtumor die behandeld 
zijn met inductie-chemotherapie. Hierbij wordt tevens de rol van de 
remediastinoscopie besproken. 
 
T3 tumoren 
Bij ongeveer 10% van de patiënten die een operatie ondergaan in verband met 
longkanker blijkt sprake te zijn van een T3 tumor. De groep van T3 tumoren 
bestaat uit longtumoren met ingroei in de thoraxwand, mediastinale structuren 
of het diafragma, Pancoast tumoren, tumoren die gelokaliseerd zijn in de 
hoofdbronchus op een afstand van minder dan 2 cm van de hoofdcarina en 
tumoren met een atelectase of obstructiepneumonie van de gehele long. De 
behandeling van deze groep tumoren bestaat in principe uit chirurgie.  
 
Hoofdstuk 2 beschrijft de resultaten van en bloc resectie en extrapleurale 
resectie bij 125 patiënten met een T3 tumor met ingroei in de thoraxwand. 
Belangrijk bij de behandeling van deze tumor is de vraag of er bij ingroei in de 
pleura parietalis standaard een en bloc resectie (verwijdering van longkwab 
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inclusief deel van de thoraxwand) verricht moet worden of dat bij sommige 
patiënten een extrapleurale resectie (verwijdering longkwab inclusief pleura 
parietalis) voldoende is.  
In deze studie werd bij patiënten met ingroei in de pleura parietalis geen verschil 
gevonden in vijfjaarsoverleving tussen beide ingrepen. Als het voor de chirurg 
mogelijk was om de pleura parietalis met zijn vingers van de ribben los te 
maken voerde hij een extrapleurale resectie uit (n=73), maar indien de tumor 
gefixeerd was aan de thoraxwand kwam de patiënt in aanmerking voor een en 
bloc resectie (n=52). Bij ruim 68% van de patiënten werd een complete resectie 
verricht. De vijfjaarsoverleving bedroeg 23% voor alle patiënten. Hierbij is een 
significant verschil in overleving gevonden tussen patiënten met een complete 
ingreep en een niet-complete resectie. Ook de aanwezigheid van metastasen in 
mediastinale lymfekleren en het peroperatief openen van de tumor waardoor er 
“tumorspil” optreedt, beïnvloeden volgens deze studie de overleving negatief. Er 
is geen verband gevonden tussen overleving en leeftijd, diepte van ingroei in de 
thoraxwand en postoperatieve radiotherapie bij patiënten met een complete 
resectie. 
 
Hoofdstuk 3 analyseert de resultaten van chirurgische behandeling van een 
groep van 108 patiënten met een centraal gelokaliseerde T3 tumor. De 
patiënten zijn onderverdeeld in patiënten met een T3 tumor ten gevolge van 
ingroei in mediastinale structuren, zoals de pleura mediastinalis, nervus 
phrenicus en het pericard, en patiënten met een tumor die gelokaliseerd is in de 
hoofdbronchus op een afstand van minder dan 2 cm van de hoofdcarina. Het 
percentage complete resecties bedroeg 64,8% en bij de meerderheid van de 
patiënten werd een pneumonectomie verricht. Deze ingreep ging gepaard met 
een toename van de ziekenhuissterfte, waarbij het optreden van een 
bronchopleurale fistel de meest voorkomende oorzaak van overlijden was. De 
vijfjaarsoverleving bedroeg 27% voor alle patiënten. Ook bij deze subgroepen 
van T3 tumoren zijn een niet-complete resectie en de aanwezigheid van 
metastasen in mediastinale lymfklieren als belangrijke prognostische factoren te 
onderscheiden. Patiënten met een tumor gelokaliseerd in de hoofdbronchus 
hadden een betere overleving dan patiënten met een tumor met ingroei in de 
mediastinale structuren, maar het verschil was niet statistisch significant.  
 
Hoofdstuk 4 geeft een overzicht van de klinische kenmerken, diagnostiek, 
stadiëring, behandeling en overleving van sulcus superior tumoren, ook wel 
Pancoast tumoren genaamd. Door hun lokalisatie in de top van de long met 
ingroei in de omringende structuren (plexus brachialis, eerste rib, sympathische 
grensstreng) veroorzaken deze tumoren specifieke klachten, zoals pijn in de 
schouder en arm en het syndroom van Horner. Afhankelijk van deze ingroei 
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wordt de tumor gestadieerd als een T3 of T4 tumor, waarbij T3 tumoren tot een 
betere overleving leiden. Zowel het niet-compleet zijn van de resectie, de 
aanwezigheid van positieve mediastinale lymfklieren en het syndroom van 
Horner hebben een negatieve invloed op de overleving. De standaard-
behandeling van deze tumor bestaat uit preoperatieve radiotherapie gevolgd 
door chirurgie, waarbij de klassieke posterieure benadering volgens Shaw-
Paulson of de nieuwere anterieure transcervicale benadering volgens Dartevelle 
de meest gebruikte technieken zijn. Hierbij wordt meestal een lobectomie van de 
bovenkwab verricht, soms met thoraxwand resectie. De gemiddelde 
vijfjaarsoverleving bedraagt ongeveer 30%. Recente resultaten van een 
gecombineerde behandeling bestaande uit inductiechemoradiotherapie gevolgd 
door chirurgie zijn veelbelovend en suggereren dat deze gecombineerde 
behandeling de beste overleving geeft voor patiënten met een Pancoast tumor. 
Gezien de toename van de ziekenhuismorbiditeit en mortaliteit tijdens deze 
behandeling zijn hierbij een strenge patiëntenselectie en adequate peri-
operatieve begeleiding van essentieel belang.  
 
T4 tumoren 
De groep van T4 tumoren bestaat uit longtumoren met ingroei in het 
mediastinum, hart, grote bloedvaten, trachea, oesofagus, wervellichaam of 
carina, tumoren met maligne pericard-of pleuravocht en tumoren met een 
metastase in dezelfde kwab als de primaire tumor. De rol van chirurgie bij de 
behandeling van deze groep van tumoren is onduidelijk. Hoewel het merendeel 
van de T4 tumoren beschouwd wordt als inoperabel, zijn bij geselecteerde 
patiënten goede resultaten beschreven na een uitgebreide chirurgische ingreep. 
De vraag is echter welke patiënten tot deze geselecteerde groep behoren.  
 
In hoofdstuk 5 worden de resultaten weergegeven van chirurgische behandeling 
van 89 patiënten met een T4 tumor. In tegenstelling tot de groep van T3 
tumoren was het aantal complete resecties bij T4 tumoren veel lager en bedroeg 
38,2%. Patiënten met ingroei in de carina, trachea en grote bloedvaten hadden 
de meeste kans op een complete resectie, waarbij meestal een pneumonectomie 
werd verricht. De ziekenhuissterfte was hoog en bedroeg 19,1%, hetgeen het 
belang van zorgvuldige patiëntenselectie benadrukt. De 5-jaarsoverleving was 
19,1% voor alle patiënten. Wederom is er een significant verschil in overleving 
gevonden tussen patiënten met een complete en een niet-complete resectie De 
beste overlevingsresultaten zijn beschreven voor de patiënten met een tumor in 
de trachea of carina, terwijl patiënten met ingroei in de grote vaten de kortste 
overleving hadden. In deze studie is geen verband gevonden tussen overleving 
en de aanwezigheid van mediastinale lymfklier-metastasen, maar de studie 
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betrof slechts een kleine groep patiënten. Leeftijd, soort operatieve ingreep en 
postoperatieve radiotherapie hadden geen significante invloed op de overleving. 
 
Tegenwoordig is multimodale behandeling, bestaande uit inductiechemo-
therapie gevolgd door radiotherapie of chirurgie, de aanbevolen therapie voor 
patiënten met stadium IIIB tumoren. Het doel van de chemotherapie is hierbij 
om de locale controle te verbeteren door “downstaging“ van de tumor en 
lymfklieruitzaaiïngen en om micrometastasen uit te roeien. Inductiechemo-
therapie bestaande uit een platinum bevattende combinatie wordt momenteel 
het meest effectief geacht en daardoor ook het meest gebruikt.  
 
In hoofdstuk 6 worden de resultaten beschreven van een prospectieve 
multicenter studie waarin 41 patiënten met een stadium IIIB niet-kleincellige 
longtumor behandeld werden met inductiechemotherapie gevolgd door 
chirurgie, radiotherapie of een combinatie van beide. Het responspercentage 
van de behandeling met de inductiechemotherapie bedroeg 66%. Bij 37% van 
de responders (n=10) werd een complete ingreep verricht. 1 patiënt is 
postoperatief overleden. Responders die geopereerd werden hadden een betere 
overleving dan responders die behandeld werden met radiotherapie. 
Belangrijke complicaties bij diegenen die geopereerd werden waren 
fistelvorming, empyeem en bloeding. Histopathologische downstaging trad op 
bij 39% van de patiënten. Deze gegevens tonen aan dat chirurgische 
behandeling na inductiechemotherapie haalbaar is bij patiënten met een 
stadium IIIB niet-kleincellige longtumor. 
In deze studie is tevens gekeken naar de diagnostische betekenis van de 
remediastinoscopie als middel voor mediastinale lymfklierstadiëring na 
inductiechemotherapie. De resultaten van dit onderzoek zijn echter teleurstellend 
door het aantal inadequate procedures ten gevolge van verbindweefseling en 
verklevingen, en het daardoor voorkomen van vals negatieve resultaten. 
 
Conclusie 
De studies in dit proefschrift bevestigen dat chirurgie de aangewezen 
behandeling is voor patiënten met een T3 tumor. Een operatie heeft echter 
alleen zin als de tumor volledig verwijderd kan worden. Bij T3 tumoren bestaat 
de ingreep daarom meestal uit een en bloc resectie van de tumor met de 
omringende structuur. T3 tumoren met ingroei in de thoraxwand zijn hierbij een 
gunstigere subgroep omdat hun perifere lokalisatie met afwezigheid van andere 
belangrijke omringende structuren de kans op het verrichten van een complete 
resectie vergroot. 
Een belangrijk punt met betrekking tot de prognose van longtumoren is de 
aanwezigheid van metastasen in mediastinale lymfklieren. Ook dit is bevestigd 
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in onze T3 studies. Het is daarom van groot belang om patiënten adequaat te 
stadiëren en pre-operatief een onderscheid te maken tussen N0-1 en N2 ziekte, 
aangezien deze laatste groep patiënten geen kandidaat is voor primaire 
behandeling met chirurgie, maar in aanmerking komt voor behandeling met 
inductiechemotherapie. 
Vergelijking van de 5-jaarsoverleving tussen de verschillende subgroepen toont 
geen significant verschil. Ook andere studies laten geen eenduidige subgroep 
met een gunstigere prognose zien. Hierbij moet vermeld worden dat het echter 
moeilijk is om deze studies met elkaar te vergelijken omdat patiëntenselectie en 
onderzoeksmethoden nogal verschillen. Om deze vraag te beantwoorden zijn 
grote vergelijkende studies tussen de diverse subgroepen nodig. 
Ook dient verder onderzoek verricht te worden naar de rol van trimodale 
behandeling. Gezien de veelbelovende resultaten van die therapie bij patiënten 
met een Pancoast tumor rijst de vraag of deze combinatie van 
inductiechemoradiotherapie gevolgd door chirurgie ook geschikt is voor andere 
T3 tumoren en dan vooral de centraal gelokaliseerde tumoren. 
In het verleden is er een duidelijk verschil gemaakt tussen T3 en T4 tumoren wat 
betreft de mogelijkheid voor chirurgische resectie. Diverse studies hebben de 
technische haalbaarheid van resectie van T4 tumoren met omringende 
structuren aangetoond, maar er zijn weinig gegevens bekend over een 
langdurige overleving. Daarnaast gaan deze uitgebreide operaties meestal 
gepaard met een hoge mortaliteit. Daarom is het van groot belang patiënten 
accuraat te stadiëren en ze te verwijzen naar een centrum met expertise in het 
uitvoeren van deze uitgebreide operaties. De beste resultaten worden 
beschreven voor T4 tumoren met ingroei in de trachea of carina.  
Gezien de gunstige resultaten van inductiechemotherapie is dit tegenwoordig de 
aanbevolen behandeling voor patiënten met een T4 tumor. Daarbij is het 
aantonen van “downstaging” door de inductiebehandeling erg belangrijk, 
aangezien patiënten met persisterende metastasen in mediastinale lymfklieren 
geen geschikte kandidaten zijn voor chirurgische behandeling.  
Resultaten van remediastinoscopie voor restadiëringsonderzoek van het 
mediastinum zijn teleurstellend ten gevolge van vals negatieve resultaten, c.q. 
het voorkomen van inadequate procedures. Daarom moeten we op zoek gaan 
naar andere restadiëringsmethoden. Positron emission tomografie (PET) scan 
speelt een belangrijke rol bij stadiëringsonderzoek. Op dit moment zijn er echter 
weinig gegevens bekend over de rol van PET in restadiëring na 
inductiebehandeling. Op dat terrein is verder onderzoek nodig. Andere in 
ontwikkeling zijnde technieken om mediastinale lymfklieren te stadiëren zijn 
endoscopische oesofageale en bronchiale echografie met naaldbiopsieën.  
Hoewel chirurgische resectie kan leiden tot effectieve lokale controle, 
ontwikkelen veel patiënten op den duur metastasen op afstand, waarvan 
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hersenmetastasen de meest voorkomende zijn. Daarom is de vraag gesteld of 
deze patiënten behandeld moeten worden met profylactische hersenbestraling 
om de overleving te verbeteren. Op dit moment zijn hierover slechts beperkte 
gegevens bekend, maar die suggereren inderdaad dat profylactische 
hersenbestraling het ontstaan van hersenmetastasen bij patiënten met een niet-
kleincellige longtumor kan verminderen. 
De afgelopen jaren heeft het gebruik van nieuwe chemotherapeutische 
middelen, gebruikt als monotherapie of in combinatie, de overleving bij 
patiënten met een niet-kleincellige longtumor verbeterd. Recent lijkt hierin 
echter, gezien de vrijwel identieke resultaten van de diverse fase III studies, een 
plateau bereikt te zijn. Vooruitgang in de moleculaire biologische kennis van 
niet-kleincellige longtumoren heeft geleid tot het ontwikkelen van nieuwe 
farmacologische middelen, zoals angiogenese remmers, tyrosine kinase 
remmers en immuuntherapie. Deze worden momenteel onderzocht in fase I en 
II trials. Of een combinatie van deze middelen met de traditionele 
behandelmogelijkheden zoals chirurgie, radiotherapie en chemotherapie, zal 
leiden tot een betere overleving zal uit verder onderzoek dienen te blijken.  
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Dankwoord 
Dit proefschrift is geschreven als de intercity tussen Roermond en Utrecht CS: 
een goede verbinding, maar met af en toe vertraging. Het doel is bereikt en het 
resultaat, dit proefschrift, ligt nu voor u. Maar promoveren doe je niet alleen, er 
zijn meer mensen betrokken bij die reis en ik heb veel baat gehad bij hun hulp. 
Zonder dat ik de illusie heb hier volledig te kunnen zijn, wil ik toch enkele 
personen in het bijzonder noemen. 
 
Allereerst dank ik dr. J.M.M. van den Bosch. Beste Jules, je hebt me de kans 
gegeven om me naast mijn werkzaamheden in de kliniek bezig te gaan houden 
met wetenschappelijk onderzoek. Zonder jouw ideeën, prikkelende 
opmerkingen en uitgebreide database was dit proefschrift nooit tot stand 
gekomen. Dank ook voor het feit dat jij me altijd vertrouwen hebt gegeven dat 
het eindstation bereikt zou worden.  
 
Prof. dr. A. Brutel de la Rivière. Beste Aart, dank voor je kritische opmerkingen, 
het aandragen van nieuwe gezichtspunten en de steun bij het meeschrijven aan 
alle manuscripten. Het tracé is volbracht. Dat niet in de laatste plaats doordat jij 
een kundig wisselwachter bent, waarvoor mijn dank. 
 
Prof. dr. J-W.J. Lammers. Beste Jan-Willem, dank voor het zorgvuldig 
beoordelen van dit proefschrift en je inspirerende opmerkingen en 
ondersteuning. Ik heb onze samenwerking tijdens deze reis als erg motiverend 
ervaren. 
 
De chirurgische behandeling vormt de hoeksteen van dit proefschrift. Op deze 
plaats wil ik dan ook Henry van Swieten en de andere thoraxchirurgen in het 
Sint Antonius ziekenhuis danken voor het verrichten van de longoperaties. 
 
Franz Schramel. Beste Franz, onder jouw supervisie ben ik op B3 de wereld van 
de chemotherapie binnengetreden. Mijn dank voor je begeleiding, dit heeft veel 
bijgedragen aan een belangrijk deel van dit traject. 
 
Ook Hans Elbers, Cees Westermann, Pieter Hofman, Vincent Duurkens en 
Klaartje Maas dank ik voor hun support aan verschillende manuscripten en hun 
waardevolle opmerkingen. 
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Joke van der Sluis. Beste Joke, dank voor je fantastische ondersteuning. Jouw 
hulp bij het verzamelen van dossiers, longfunctie kaarten, het invoeren van 
gegevens en het opvragen van data was van zeer grote waarde. 
 
Alle voormalige collega’s en medewerkers van de afdeling longziekten in het 
Sint Antonius ziekenhuis in Nieuwegein. Ik heb er een leerzame en gezellige 
opleidingstijd gehad waaraan ik graag terugdenk. Een speciaal woord van dank 
aan René Hage, die mij als ervaren reiziger zeer waardevolle reistips heeft 
gegeven. 
 
Mijn huidige collega’s in het Laurentius ziekenhuis in Roermond. Beste Louis en 
Irwan, hoewel het grootste deel van dit onderzoek stamt uit mijn 
opleidingsperiode, hebben jullie me extra ruimte gegeven om het nu te kunnen 
voltooien.  
Ook alle medewerkers van de afdeling longziekten dank ik voor hun interesse 
en hun hulp bij de laatste loodjes. 
 
Tiny Wouters wil ik bedanken, omdat zonder haar dit boek er nooit zo mooi zou 
hebben uitgezien.  
 
Niet alleen collega’s, maar ook familie en vrienden zijn onmisbaar. Zonder 
jullie steun en belangstelling had ik deze reis niet kunnen voltooien. 
 
Mijn paranimfen, Pieternel en Hazel. Zonder jullie support, hetzij (urenlang?) 
telefonisch of persoonlijk in het hoge noorden of verre zuiden, hetzij genietend 
van de oneindige stilte in “ons Blockhaus”, zou het leven een stuk minder laat, 
dus minder leuk zijn. Dank voor jullie vriendschap! 
 
Tenslotte, Marlof, jij was mijn allerbelangrijkste medepassagier tijdens deze 
spannende reis. Dank je voor je steun, liefde en begrip. Deze reis is nu voltooid, 
maar gelukkig staat ons volgend reisdoel al weer vast. Samen komen we nog 
eens ergens. 2004 is een heel bijzonder jaar! 
 
 
En verder iedereen die op enige wijze aan de totstandkoming van dit proefschrift 
heeft bijgedragen: mijn dank! 
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Curriculum vitae 
De auteur van dit proefschrift werd geboren op 13 juni 1967 te Heerlen. In 
1985 behaalde zij haar Gymnasium-$ diploma aan de Scholengemeenschap 
Sint Michiel te Geleen.  
Aansluitend studeerde zij geneeskunde aan de Universiteit Utrecht, waar zij in 
december 1992 haar artsexamen behaalde. 
Van maart 1993 tot juli 1995 is zij werkzaam geweest als AGNIO longziekten in 
het Sint Antonius Ziekenhuis in Nieuwegein. In juli 1995 startte zij met haar 
vooropleiding interne geneeskunde in het Diakonessenhuis te Utrecht (opleider 
dr. J.B.L.Hoekstra). De opleiding tot longarts vond plaats in het Sint Antonius 
Ziekenhuis te Nieuwegein, (opleiders achtereenvolgend dr. R.G.J.R.A. 
Vanderschueren en dr. J.M.M. van den Bosch) en een half jaar in het 
Universitair Medisch Centrum Utrecht (opleider prof. dr. J-W. J. Lammers).  
Sinds januari 2001 is zij werkzaam als longarts in het Laurentius Ziekenhuis te 
Roermond. 
 
 
